capecitabine has been researched along with Stomach Neoplasms in 542 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.37) | 18.2507 |
| 2000's | 98 (18.08) | 29.6817 |
| 2010's | 366 (67.53) | 24.3611 |
| 2020's | 76 (14.02) | 2.80 |
| Authors | Studies |
|---|---|
| Cairns, DA; Hall, PS; Seymour, MT | 1 |
| Mizutani, T | 1 |
| Kim, DH; Wang, X; Wei, LJ | 1 |
| Branagan-Harris, M; Horvath, P; Javanbakht, M; Königsrainer, A; Mashayekhi, A; Reymond, MA; Yaghoubi, M | 1 |
| Iyama, A; Nakamura, H; Nakamura, J; Satoh, K | 1 |
| Armisén, R; Bravo, ML; Cordova-Delgado, M; Corvalán, AH; Cumsille, E; Garrido, M; Hill, CN; Lavanderos, MA; Li, Z; Liao, Y; Miquel, JF; Muñoz-Medel, M; Owen, GI; Pinto, MP; Quiñones, LA; Retamal, IN; Rodriguez-Fernandez, M | 1 |
| Boku, N; Cai, Z; Hironaka, S; Komatsu, Y; Piao, Y; Tanizawa, Y | 1 |
| Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D | 1 |
| Chen, ZY; Feng, WJ; Geng, QR; Gong, Z; Guo, WJ; He, YF; Huang, MZ; Ji, JM; Li, WH; Liu, QQ; Liu, X; Luo, JF; Qin, YR; Qiu, LX; Song, XF; Wang, CC; Wang, Q; Wang, XF; Wang, YS; Wu, J; Wu, SS; Xu, Q; Yang, L; Ying, JE; Zhang, CY; Zhang, JY; Zhang, W; Zhang, XW; Zhang, Z; Zhao, J; Zhao, XY; Zheng, H; Zhu, XD; Zou, JL | 1 |
| Ding, P; Guo, H; Kim, NH; Li, Y; Liu, P; Liu, Y; Sun, C; Tian, Y; Yang, P; Zhao, Q | 1 |
| Bai, F; Gan, W; He, Z; Zhou, H | 1 |
| Amoroso, D; Barni, S; Bernardini, I; Bilancia, D; Casaretti, R; Cascinu, S; Casolaro, A; Cavanna, L; Cella, CA; Ciarlo, A; Codecà, C; Davite, C; Di Sanzo, A; Labianca, R; Luchena, G; Mosconi, S; Prisciandaro, M; Rosati, G; Silvestris, N; Zoratto, F | 1 |
| Akamaru, Y; Endo, S; Fujita, S; Fujitani, K; Goto, M; Imano, M; Kato, T; Kawabata, R; Kawakami, H; Kurokawa, Y; Lee, SW; Matsuyama, J; Sakai, D; Satoh, T; Shimokawa, T; Taniguchi, H; Tatsumi, M; Terazawa, T | 1 |
| Choi, GE; Jang, A; Jin, H; Ju, Y; Kim, J; Seol, YM | 1 |
| Cai, Q; Guo, L; Liu, J; Shangguan, C; Shi, M; Shi, Y; Wu, J; Xi, W; Yang, H; Zhang, J; Zhou, C | 1 |
| Chen, J; Hollebecque, A; Kepp, O; Kroemer, G; Liu, P; Zhao, L; Zitvogel, L | 1 |
| Dubashi, B; Ganesan, P; Ganesh, RN; Jafa, E; Kate, V; Kayal, S; L, C; Nisha, Y; Penumadu, P; V C, S | 1 |
| Ahn, MS; Choi, JH; Choi, YW; Kang, SY; Kim, H; Kim, TH; Lee, HW; Park, M | 1 |
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
| Aoki, R; Imai, Y; Kano, S; Kezuka, C; Mikame, Y; Nakazawa, T; Okuda, Y; Otsuka, Y; Saito, T; Sanbe, R; Sato, R; Shinada, M; Wakamori, M; Yamaguchi, H | 1 |
| Guan, Q; He, L; Lian, X; Shen, J; Zhang, F | 1 |
| Glehen, O; Karoui, M; Mariani, A; Zaanan, A | 1 |
| Chung, IJ; Hong, YS; Kang, WK; Kang, YK; Kim, YH; Lee, KH; Nam, BH; Park, YI; Park, YS; Ryoo, BY; Ryu, MH; Shen, L; Shin, DB; Yang, SH; Yeh, KH; Yoo, C; Zang, DY | 1 |
| Ang, JJ; Chia, DKA; Kim, G; Shabbir, A; So, JBY; Sundar, R; Yong, WP | 1 |
| Gao, S; Luo, S; Ma, H; Sun, H; Yuan, Z; Zhan, X; Zhang, L; Zhang, Y; Zhao, N | 1 |
| Choi, IS; Han, HS; Kim, JW; Kim, KH; Kim, MJ; Ko, YH; Koh, SA; Koo, DH; Lee, KW; Lee, SS; Nam, BH; Park, JH; Ryu, MH; Sohn, BS; Zang, DY | 1 |
| Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V | 1 |
| Ajani, JA; Arozullah, A; Bang, YJ; Bhattacharya, P; Enzinger, P; Gallego Plazas, J; Huang, J; Ilson, D; Lordick, F; Moran, D; Oh, M; Oh, SC; Park, JW; Shah, MA; Shen, L; Shitara, K; Soo Hoo, HF; Sunpaweravong, P; Turk, HM; Van Cutsem, E; Xu, RH | 1 |
| Imoto, S; Miyano, S; Park, H | 1 |
| Kim, H; Kim, M; Maeng, CH | 1 |
| Derks, S; van Laarhoven, HWM | 1 |
| Shi, JW; Wu, S; Zhou, Y | 1 |
| Dirani, K; Juzych, D; Marusca, G; Wang, J | 1 |
| Aoyama, T; Chin, K; Hatori, M; Kawakami, K; Kimura, Y; Kobayashi, K; Nakamura, M; Nakayama, I; Ogura, M; Shimizu, H; Suzuki, K; Suzuki, W; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yamaguchi, M; Yokokawa, T | 1 |
| Bai, Y; Cang, S; Gu, K; Guo, Q; Guo, Y; Han, L; He, Y; Jiang, H; Li, J; Li, Z; Liang, X; Ling, Y; Liu, Y; Luo, S; Mao, Y; Niu, Z; Pan, H; Pan, Y; Peng, B; Qin, Y; Shu, Y; Tang, Y; Wang, Y; Xu, J; Yan, Z; Yang, J; Yang, L; Zhang, J; Zhang, L; Zhao, J; Zhou, H | 1 |
| Anthoney, DA; Collins, L; Eatock, M; Elhussein, L; Falk, S; Goff, M; Lord, SR; Love, S; Middleton, MR; Moschandreas, J; Thomas, A; Turkington, RC; Virdee, PS | 1 |
| Calomino, N; Cherri, S; Farsi, M; Fiaschi, AI; Francini, E; Francini, G; Marrelli, D; Miano, ST; Petrioli, R; Rovello, F; Savelli, V; Vernillo, R | 1 |
| Jung, YJ; Kim, IH; Lee, HH; Lee, J; Lee, SH; Park, CH; Park, JM; Park, SJ; Roh, SY; Seo, HS; Shin, K; Song, KY | 1 |
| Feliu, J; Ghanem, I; Higuera, O; Perez-Wert, P; Rodriguez-Salas, N; Viñal, D | 1 |
| Bapat, B; Brown, J; Candrilli, SD; García-Foncillas, J; Kaye, JA; Liepa, AM; Lorenzen, S; Madhwani, S | 1 |
| Jain, A | 1 |
| Mini, E; Roviello, F; Roviello, G | 1 |
| Adenis, A; Mazard, T; Mourregot, A; Portales, F; Samalin, E; Ychou, M | 1 |
| Allahyari, A; Barri, A; Bondad, N; Boostani, R; Elyasi, S | 1 |
| Cui, C; Jiang, Z; Sun, Y; Yang, L; Zhang, W; Zhou, A | 1 |
| Aoyama, T; Hara, K; Hayashi, T; Kumazu, Y; Masuda, M; Morinaga, S; Nagasawa, S; Nakazono, M; Numata, M; Ogata, T; Oshima, T; Rino, Y; Shimoda, Y; Shiozawa, M; Tamagawa, H; Yamada, T; Yukawa, N | 1 |
| He, S; Huang, C; Huang, L; Li, Q; Liao, X; Yu, Q; Yuan, X | 1 |
| Akiyoshi, K; Hirao, M; Kimura, Y; Kurokawa, Y; Murakami, K; Sakai, D; Sato, T; Shimokawa, T; Sugimoto, N; Takeno, A | 1 |
| Feng, J; Feng, Z; He, X; Hou, X; Yan, P; Yang, K | 1 |
| Fan, L; Guo, H; Huo, Z; Li, M; Li, Y; Lian, C; Liu, Y; Tan, B; Tian, Y; Wang, D; Yang, P; Zhang, Z; Zhao, Q; Zhao, X | 1 |
| Deng, X; He, D; He, Y; Jiang, D; Jin, W; Liu, X; Owen, G; Shu, C; Sun, L; Zhang, M; Zhang, W | 1 |
| Cao, J; Chen, Z; Wang, W; Wu, J; Yan, H; Yang, W; You, Y; Zhang, Q; Zhang, X; Zhao, D | 1 |
| Amarantidis, K; Balgkouranidou, I; Biziota, E; Bolanaki, H; Chatzaki, E; Kakolyris, S; Karamitrousis, E; Karayiannakis, A; Kolios, G; Koukaki, T; Lambropoulou, M; Lianidou, E; Trypsianis, G; Xenidis, N | 1 |
| Hu, CG; Liu, J; Xue, D; Xue, YF; Yao, B | 1 |
| Carlei, F; De Donato, MC; Di Cesare, E; Di Sibio, A; Ficorella, C; Giuliani, A; Latessa, M; Monti, R; Parisi, A; Romano, L; Schietroma, M; Varrassi, M; Venditti, O | 1 |
| Bang, YJ; Boku, N; Bragagnoli, AC; Coşkun, HS; Cubillo Gracian, A; Dvorkin, M; Hong, J; Lonardi, S; Moehler, M; Muntean, AS; Nechaeva, M; Özgüroğlu, M; Ryu, MH; Safran, H; Silver, MR; Taieb, J; Takano, T; Vaccaro, GM; Wainberg, ZA; Wong, R; Xiong, H | 1 |
| Fei, MY; Fei, Y; Huang, SX; Pan, XP | 1 |
| An, JY; Bae, JM; Choi, MG; Hong, JY; Hwang, IG; Ji, JH; Kang, JH; Kang, WK; Kim, KM; Kim, S; Kim, ST; Lee, J; Lee, JH; Lim, DH; Lim, HY; Oh, SY; Park, JO; Park, SH; Park, YS; Shin, DB; Sohn, TS; Yu, JI; Zang, DY | 1 |
| Kim, EJ; Kim, M; Kim, MJ; Park, SR; Seo, S | 1 |
| Abe, S; Ami, K; Hamasaki, S; Harada, T; Katsuno, A; Kitagawa, Y; Machida, T; Nakanishi, A; Tamura, N; Umetani, N | 1 |
| Alsina, M; Aranda, E; Falcó, E; Fernández, E; Galán, M; Gallego, J; García-Alfonso, P; González, E; Izquierdo-Manuel, M; Jiménez-Fonseca, P; Jorge, M; Limón, ML; López, C; López, L; Manzano, JL; Martínez de Castro, E; Muñoz-Unceta, N; Rivera, F | 1 |
| Acar, R; Akkuş, E; Altınbaş, M; Çınkır, HY; Çubukçu, E; Demir, A; Demiray, AG; Ergün, Y; Erol, C; Gürbüz, M; Güven, DC; Karadurmuş, N; Karaoğlan, M; Kılıçkap, S; Şahin, AB; Şahin, S; Şakalar, T; Sakin, A; Şendur, MAN; Şenler, FÇ; Turhal, NS; Türker, S; Uncu, D; Urvay, S; Üskent, N | 1 |
| Bai, Y; Chen, B; Liu, K; Ma, Z; Xu, J | 1 |
| Dong, M; Li, X; Liu, D; Wang, H | 1 |
| Al-Batran, SE; Ganguli, A; Lordick, F; Morlock, R; Sahin, U; Türeci, Ö | 1 |
| Chen, Y; Gou, H; Hu, J; Leng, W; Ni, L; Qiu, M; Zhang, W | 1 |
| Ashabi, G; Halimi, S; Nabavizadeh, F; Panahi, M; Rahimi, AM; Rahimpour, M; Vahedian, J | 1 |
| Adelberg, D; Bang, YJ; Bhagia, P; Fuchs, CS; Janjigian, YY; Li, K; Qin, SK; Tabernero, J; Van Cutsem, E | 1 |
| Abali, H; Artac, M; Basal, FB; Baygul, A; Budakoglu, B; Camci, C; Dane, F; Goktas, B; Karabulut, B; Mertsoylu, H; Oksuzoglu, B; Onal, HC; Ozdemir, N; Ozdener, F; Sendur, MAN; Yalcin, S | 1 |
| Allmark, C; Cairns, DA; Chatterjee, A; Crossley, A; Cummins, S; Dent, J; Falk, S; Garcia, A; Grabsch, HI; Grumett, S; Guptal, K; Hall, PS; Handforth, C; Howard, H; Kamposioras, KV; Katona, E; Khan, M; Lord, S; Maisey, N; Mano, J; Marshall, H; Nicoll, J; Ow, PL; Petty, R; Roy, R; Ruddock, S; Seymour, MT; Stokes, Z; Swinson, D; Tillett, T; Velikova, G; Waddell, T; Wadsley, J; Waters, JS | 1 |
| Claringbold, PG; Grover, P; Kesavan, M; Lam, WS; Turner, JH | 1 |
| Kumar, S; Maria Das, KJ; Misra, S; Singh, RK; Singh, S; Yeshala, SK | 1 |
| Cui, Y; Li, Y; Liu, X; Qu, A; Sun, Y; Tian, W; Wang, F; Wei, B; Zhang, J | 1 |
| Qian, Y; Yin, Y; Zhang, Q | 1 |
| Hayashi, T; Kamiya, A; Katai, H; Otsuki, S; Sekine, S; Wada, T; Yamagata, Y; Yoshikawa, T | 1 |
| Gęca, K; Małecka-Massalska, T; Mlak, R; Pelc, Z; Polkowski, WP; Rawicz-Pruszyński, K; Sędłak, K; Skórzewska, M | 1 |
| Agarwal, R; Grieb, BC | 1 |
| Amlashi, FG; Blum Murphy, M; Bozkurt, M | 1 |
| Li, H; Li, W; Liang, L; Liu, T; Song, D; Zhao, N | 1 |
| Anderegg, MCJ; Gisbertz, SS; Hulshof, MCCM; Los, M; Mohammed, NH; Ruurda, JP; van Berge Henegouwen, MI; van der Sluis, PC; van Hillegersberg, R; van Laarhoven, HWM; van Vulpen, M; Wiezer, MJ | 1 |
| Huang, ZP; Li, GX; Wang, F; Wang, ZX; Xu, RH; Zhou, ZW | 1 |
| Baars, A; de Mol, P; Kok, WEM; Koopman, M; Kwakman, JJM; Punt, CJA; van Zweeden, AA | 1 |
| Chu, Y; Li, Y; Song, R; Xu, F | 1 |
| Gritli, I; Inoue, K; Kadowaki, S; Muro, K; Nishina, T; Ozeki, A; Piao, Y; Sakai, D; Shitara, K; Yoshikawa, R | 1 |
| Adachi, Y; Mizukami, Y; Nomura, H; Okamura, M; Ota, S; Sumii, A; Tsuboi, K | 1 |
| Anderegg, MCJ; Mohammad, NH; Ngai, LL; Ter Veer, E; Valkenhoef, GV; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Alessi, A; Battiston, C; Berenato, R; Caporale, M; Coppa, J; Cotsoglou, C; de Braud, F; Delconte, G; Di Bartolomeo, M; Fucà, G; Greco, G; Infante, G; Lazzati, S; Mazzaferro, V; Mennitto, A; Morano, F; Niger, M; Padovano, B; Pellegrinelli, A; Pietrantonio, F | 1 |
| Kim, HB; Park, SG | 1 |
| Ang, A; Doi, T; Jung, AS; Komatsu, Y; Muro, K; Nakajima, TE; Nishina, T; Tang, R; Yamaguchi, K; Yang, H; Yasui, H; Zhang, Y | 1 |
| Cho, JH; Cho, JY; Lim, JY | 1 |
| Ciardiello, F; De Vita, F; Di Martino, N; Laterza, MM; Orditura, M; Pappalardo, A; Petrillo, A; Pompella, L; Tirino, G; Troiani, T | 1 |
| Gong, Y; Li, GF; Yu, G | 1 |
| Chu, MP; Sawyer, MB | 1 |
| Gu, W; Shan, B; Wang, L | 1 |
| Hussaarts, KGAM; Mathijssen, RHJ; van Leeuwen, RWF | 1 |
| Arakawa, Y; Hayashi, K; Nagasaki, E; Nakada, K; Tamura, M; Uwagawa, T; Yano, S | 1 |
| Kim, MJ; Kim, S; Kong, SY; Nam, BH; Park, SR; Park, YI | 1 |
| Cheng, X; Lu, Y | 1 |
| Boesveldt, S; de Graaf, C; de Vries, YC; Kampman, E; van Laarhoven, HWM; Winkels, RM | 1 |
| Arita, T; Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nishibeppu, K; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Kamata, T; Nakayama, A; Sato, N; Takai, Y | 1 |
| Arisaka, S; Fukushima, T; Hasegawa, S; Hashimoto, I; Hayashi, T; Hirakawa, S; Ike, H; Imada, T; Masuda, M; Murakami, H; Rino, Y; Segami, K; Shimada, K; Sugawara, Y; Takagawa, R | 1 |
| Chae, H; Kim, HI; Kim, IH; Kim, MC; Kwon, IK; Lee, CM; Lee, HH; Lee, SI; Min, JS; Park, SS | 1 |
| Creemers, A; de Waal, L; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Ding, C; Jiao, XD; Yu, G; Zang, YS | 1 |
| Chen, LT; Chin, YY; Chu, NS; Wu, IC | 1 |
| Qiu, H; Zhou, Z | 1 |
| Hoehler, T; Kanzler, S; Kunzmann, V; Lordick, F; Maderer, A; Meyer, HJ; Mihaljevic, AL; Moehler, M; Mönig, S; Sandermann, A; Schroll, S; Schuhmacher, C; Stahl, M; Tannapfel, A; Thuss-Patience, P; Wilke, H | 1 |
| Braak, JPBM; Cats, A; Claassen, YHM; de Steur, WO; Dikken, JL; Hartgrink, HH; Jansen, EPM; Meershoek-Klein Kranenbarg, WM; Putter, H; Trip, AK; van Berge Henegouwen, MI; van de Velde, CJH; van Grieken, NCT; van Sandick, JW; Verheij, M | 1 |
| Chen, Y; Dai, G; Gu, X; Shi, Y; Wang, Y; Yin, H | 1 |
| Duan, X; Liu, S; Wang, K; Wu, J; Zhang, B; Zhang, D | 1 |
| An, JY; Kim, S; Kim, SM; Lee, J; Sohn, TS | 1 |
| Hasegawa, H; Kakeji, Y; Kanaji, S; Maehara, R; Matsuda, T; Matsuda, Y; Nakamura, T; Oshikiri, T; Sumi, Y; Suzuki, S; Yamamoto, M; Yamashita, K | 1 |
| Cai, Z; Chen, Z; Shen, C; Wang, J; Yin, X; Yin, Y; Zhang, B; Zhou, Y | 1 |
| Liu, S; Peng, J; Tan, C; Zeng, X | 1 |
| Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y | 1 |
| Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P | 1 |
| Doi, T; Okino, T; Sakamoto, T | 1 |
| Abbassi, MM; Eldeib, HK; Hussein, MM; Sabry, NA; Salem, SE | 1 |
| Ji, J; Jia, Y; Li, S; Li, Z; Miao, R; Pang, F; Ren, H; Shan, F; Wang, Y; Xue, K; Yan, C; Ying, X; Zhang, L; Zhang, Y | 1 |
| Fan, B; Guo, Q; Luo, Y; Shen, C; Wu, M; Zhao, J | 1 |
| Diker, O; Dizdar, O; Karakas, Y; Vural, S | 1 |
| Bilici, A; Erkol, B; Figen, M; Surmelioglu, A; Tilki, M; Ustaalioglu, BBO; Uyar, S | 1 |
| Aparicio, T; Azzedine, A; Barbier, E; Bouche, O; Chapelle, N; Cohen, R; Dahan, L; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Le Malicot, K; Lepage, C; Louvet, C; Mineur, L; Nguyen, S; Phelip, JM; Samalin, E; Sefrioui, D; Touchefeu, Y | 1 |
| Ahn, JY; Jung, HY; Kang, YK; Lee, GH; Park, SR; Park, Y; Park, YS; Ryoo, BY; Ryu, MH; Seo, S | 1 |
| Cheng, X; Cui, Y; Ji, Y; Jiang, H; Li, W; Liu, F; Liu, TS; Shen, Z; Sun, Y; Tang, C; Wang, X; Wang, Y; Yu, S; Yu, Y | 1 |
| Klaassen, R; Lambin, P; Larue, RTHM; Mearadji, B; Stoker, J; van der Woude, SO; van Laarhoven, HWM | 1 |
| Fujikawa, K; Hamaguchi, K; Okagawa, Y; Sagawa, T; Sakurada, A; Takahashi, Y; Tamura, F; Uemura, N | 1 |
| Brown, TJ; Gupta, A; Uberoi, AS | 1 |
| Bando, H; Chin, K; Cho, H; Emi, Y; Fukunaga, T; Gotoh, M; Hirao, M; Ishibashi, T; Katai, H; Kawashima, Y; Misawa, K; Nakamura, Y; Oki, E; Sasako, M; Shitara, K; Terashima, M; Yamanaka, T; Yoshida, K | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Azuma, M; Boku, N; Chen, LT; Cho, H; Chung, HC; Fumita, S; Hara, H; Kang, WK; Kang, YK; Kato, K; Komatsu, Y; Lee, KW; Minashi, K; Ryu, MH; Tsuda, M; Yamaguchi, K | 1 |
| Dijksterhuis, WPM; Klaassen, R; Kurk, SA; Pruijt, MJ; van der Woude, SO; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Naito, A; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A; Yukawa, Y | 1 |
| Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nanishi, K; Okamoto, K; Otsuji, E; Shiozaki, A; Shoda, K | 1 |
| Hama, N; Hamakawa, T; Hirao, M; Kato, T; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nagae, A; Nishikawa, K; Sekimoto, M; Uemura, M | 1 |
| Bowrey, DJ; Chung, WY; Dennison, AR; Eltweri, AM; Morgan, B; Thomas, AL; Thompson, J | 1 |
| Chen, L; Cong, X; Hao, Y; Li, S; Song, H; Xue, Y; Zhu, L; Zou, M | 1 |
| Iorio, R; Luigetti, M; Nicoletti, T; Spagni, G | 1 |
| Ålgars, A; Kemppainen, J; Ristamäki, R; Salminen, P; Sundström, J; Vihervaara, H | 1 |
| He, D; Liang, Y; Liu, L; Meng, J; Xia, L; Xie, X; Xu, R | 1 |
| Arrazubi, V; Barriuso, J; García-Alfonso, P; Izquierdo-Manuel, M; Jimenez-Fonseca, P; Jimeno, R; Jorge, M; López, C; Martínez, E; Méndez, JC; Muñoz-Unceta, N; Reboredo, M; Rivera, F; Romero, C; Salud, A | 1 |
| Chu, G; Salzman, J | 1 |
| Cho, H; Kang, YK | 1 |
| An, J; Bae, JM; Choi, MG; Di Bartolomeo, M; Fucà, G; Kang, WK; Kim, KM; Kim, S; Kim, ST; Lee, J; Lee, JH; Lim, DH; Miceli, R; Morano, F; Park, SH; Pietrantonio, F; Raimondi, A; Sohn, TS | 1 |
| Ilijevec, B; Jagric, T; Ocvirk, J; Potrc, S; Velenik, V | 1 |
| Chin, HM; Chung, WC; Jun, KH; Kim, YJ | 1 |
| Caballero, C; Cats, A; Elme, A; Grabsch, HI; Kang, YK; Lordick, F; Marreaud, S; Martens, U; Mauer, M; Moehler, MH; Mueller, L; Rha, SY; Thuss-Patience, P; Tokunaga, M; Wagner, AD | 1 |
| Chen, J; Guo, Y; Lin, Z | 1 |
| Demlova, R; Hacker, U; Hasenclever, D; Lordick, F; Obermannova, R; Selingerova, I; Valik, D; Zdrazilova-Dubska, L | 1 |
| Bai, Y; Gao, L; Jin, X; Wu, S | 1 |
| Xu, X; Zhang, T; Zhao, Y; Zheng, G; Zheng, Z | 1 |
| Allum, WH; Blazeby, JM; Cafferty, FH; Cunningham, D; Grabsch, HI; Griffin, SM; Langley, RE; Rowley, S; Smyth, EC | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ | 1 |
| Chen, Z; Guan, Q; Guo, Q; Li, Q; Liu, M; Wang, J; Wang, Y; Ye, Y; Zhou, Y | 1 |
| Lu, Y; Sun, Y; Wang, Z; Zheng, S; Zhou, Y | 1 |
| Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J | 1 |
| Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY | 1 |
| Boda-Heggemann, J; Haneder, S; Hochhaus, A; Hofheinz, RD; Lohr, F; Michaely, H; Ronellenfitsch, U; Schneider, V; Weiss, C; Wenz, F; Wertz, H | 1 |
| Anagnostopoulos, A; Athanasiadis, A; Boukovinas, I; Georgoulias, V; Kachris, S; Lambrodimou, G; Makrantonakis, P; Polyzos, A; Saridaki, Z; Souglakos, J; Stoltidis, D | 1 |
| Ilson, DH | 1 |
| Costa, FP; Gumz, B; Pasche, B | 1 |
| Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P | 1 |
| Barbachano, Y; Chau, I; Coxon, F; Crosby, T; Cunningham, D; Falk, S; Ferry, D; Frances, A; Gonzalez, D; Iveson, T; Mansoor, W; Middleton, G; Okines, AF; Okines, C; Peckitt, C; Saffery, C; Slater, S; Smith, D; Waddell, T; Wadsley, J; Waters, J; Wotherspoon, A | 1 |
| Bodoky, G; Celik, I; Chung, HC; Gorbunova, V; Götte, H; Kang, YK; Kurteva, G; Lordick, F; Melezínková, H; Moehler, M; Moiseyenko, VM; Oh, SC; Park, JO; Salman, P; Sawaki, A; Volovat, C | 1 |
| Huang, Y; Li, WH; Li, YQ; Liu, N; Liu, SG; Liu, XB; Liu, YH; Wang, FL; Yu, J; Yuan, ST; Zhang, JD; Zhang, Y | 1 |
| Du, Z; He, J; He, X; Li, M; Li, Q; Tang, R; Wen, F; Yin, X; Zhang, P; Zhou, Y | 1 |
| Bowrey, DJ; Cunnell, M; Khanna, A; Madhusudan, S; Parsons, SL; Reece-Smith, AM; Thomas, A | 1 |
| Chongqing, T; Gannong, C; Jianhe, L; Lihui, O; Liubao, P; Siying, W; Xiaohui, Z; Xiaomin, W; Ziying, Z | 1 |
| Kang, YK; Kim, SY; Koo, DH; Lee, CW; Maeng, J; Na, YS; Park, I; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| He, YL; Schwarz, RE; Smith, DD; Wei, ZW; Wu, Y; Xia, GK; Zhang, CH | 1 |
| Jiang, ZM; Wei, Y; Xie, DR; Yang, Q; Zhang, YD; Zhou, SW | 1 |
| Ebata, T; Fukaya, M; Hirata, A; Igami, T; Itatsu, K; Nagino, M; Sugawara, G; Tsunoda, N; Uehara, K; Usui, H; Yokoyama, Y; Yoshioka, Y | 1 |
| Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T | 1 |
| Fujitani, K | 1 |
| Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ | 1 |
| Do, IG; Jung, SH; Kang, WK; Kim, KM; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
| Arnold, D; Geissler, M; Grothe, W; Hofheinz, RD; Moehler, M; Reinacher-Schick, A; Schmoll, HJ; Seufferlein, T; Stein, A; Thuss-Patience, PC | 1 |
| Fan, Y; Hou, K; Li, C; Liu, Y; Qu, X; Xu, L; Zhang, Y; Zheng, H; Zhu, Y | 1 |
| Barnadas, A; Barriuso, J; Casado, E; Gallego, R; Garcia Foncillas, J; Garcia-Albeniz, X; Iranzo, V; Juez, I; Martin-Richard, M; Maurel, J; Pericay, C; Queralt, B; Saigi, E; Visa, L | 1 |
| Popa, EC; Shah, MA | 1 |
| Bang, YJ; Khosravan, R; Lechuga, MJ; Lee, KW; Lee, SY; Lin, X; Oh, DY; Park, SR; Park, YI; Roh, EJ; Valota, O | 1 |
| Chou, CY; Hsieh, CI; Ko, JH; Wang, KH | 1 |
| Feng, J; Gao, J; Han, Y; Huang, H; Qu, L; Shen, L; Shou, C; Zhu, L | 1 |
| Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z | 1 |
| Isikli, L; Yoney, A | 1 |
| Ahn, KS; Chen, L; Kumar, AP; Li, F; Manu, KA; Sethi, G; Shanmugam, MK; Siveen, KS | 1 |
| Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ | 1 |
| Boot, H; Cats, A; Jansen, EP; Ponz, OB; Stiekema, J; Trip, AK; van Sandick, JW; Verheij, M | 1 |
| Arena, MG; Barba, M; Belli, F; Di Lauro, L; Fattoruso, SI; Giannarelli, D; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Chen, G; Li, J; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X; Zhao, Z | 1 |
| He, MM; Luo, HY; Qiu, MZ; Ren, C; Wang, F; Wang, FH; Wang, ZQ; Wu, WJ; Xu, RH; Zeng, ZL; Zhang, DS | 1 |
| Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Wang, D; Yang, PG; Zhang, ZD; Zhao, Q; Zhao, XF | 1 |
| Aono, T; Deguchi, K; Deguchi, T; Fukui, A; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Noguchi, Y; Nomura, M; Okumura, Y; Takagi, M; Tamagawa, H; Tanaka, Y; Yoshida, H | 1 |
| Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Oshima, S | 1 |
| Hirakawa, K; Kashiwagi, S; Kawajiri, H; Noda, S; Onoda, N; Takashima, T | 1 |
| Arango, B; Escobar, M; Hosein, PJ; Kittaneh, M; Kyriakopoulos, C; Loaiza-Bonilla, A; Merchan, JR; Ochoa, RE; Palacio, S; Restrepo, MH; Rocha Lima, CM | 1 |
| Chen, FW; Egbert, BM; Sarin, KY; Swetter, SM; Zhou, X | 1 |
| Bai, C; Bai, Y; Cheng, Y; Fan, Q; Gong, J; Hu, B; Hu, G; Jiao, S; Liang, J; Liu, Y; Shen, L; Shi, Y; Wang, J; Xu, N; Xu, R; Zhang, F; Zhang, J; Zhang, X; Zheng, L | 1 |
| Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX | 1 |
| Bai, Y; Chu, YP; Gong, JF; Li, J; Li, Y; Shen, L; Zhang, XT | 1 |
| Cosson, VF; Lehle, M; Lum, BL; Ng, VW | 1 |
| Bai, LY; Chao, Y; Chen, JS; Hsieh, JS; Li, CP; Su, WC; Su, YC; Tai, CJ; Wu, CC; Yeh, HT; Yeh, KH | 1 |
| Gong, JF; Li, J; Li, Y; Lu, M; Lu, ZH; Shen, L; Wang, XC; Zhang, XT; Zhou, J | 1 |
| Al-Batran, SE; Gencer, D; Hartmann, JT; Hochhaus, A; Hofheinz, RD; Kripp, M; Merx, K; Miranda, MB | 1 |
| Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S | 1 |
| Fang, H; Jin, J; Li, YX; Liu, XF; Liu, YP; Ren, H; Song, YW; Wang, SL; Wang, WH; Wang, X; Yu, ZH | 1 |
| He, Y; Huang, C; Ji, J; Liang, H; Liu, Y; Shi, Y; Sun, Y; Wu, A; Yan, M; Ye, Y; Zhan, Y | 1 |
| Deng, D; Shen, L; Wang, M | 1 |
| Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Feng, Y; Hou, J; Ji, Y; Li, W; Liu, TS; Qin, XY; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, YY | 1 |
| Rau, B | 1 |
| Kalachand, R; King, S; Mongan, AM; Muldoon, C; O'Byrne, K; O'Farrell, NJ; Power, D; Ravi, N; Reynolds, JV | 1 |
| Sakamoto, K; Sakashita, K; Sawada, R; Sunami, T; Tauchi, J; Yukimoto, K | 1 |
| Allison, DE; Han, K; Jin, J; Lowe, J; Maia, M; Sersch, MA | 1 |
| Grin, A; Grover, SC; Maggo, G | 1 |
| Al-Sakaff, N; Bang, YJ; Chung, HC; Gotovkin, EA; Hamamoto, Y; Hill, J; Kang, YK; Moiseyenko, VM; Ohtsu, A; Satoh, T; Urspruch, A; Van Cutsem, E; Weber, HA | 1 |
| Bang, YJ; Barriuso, J; Garg, A; Kang, YK; Rha, SY; Szado, T; Tassone, P; Yu, R | 1 |
| Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M | 1 |
| Castro-Rojas, C; Ortiz-Lópezj, R; Rojas-Martínez, A | 1 |
| Dong, B; Gao, J; Gong, J; Li, Y; Li, Z; Lu, Z; Shen, L; Yu, J; Zhang, X | 1 |
| Bai, B; Cui, Y; Kuang, S; Wen, Y | 1 |
| Hong, YS; Jeon, EK; Kim, HK; Ko, YH; Park, JC; Park, SY; Shim, BY; Sun, DS; Won, HS | 1 |
| Chen, LH; Liu, TF; Liu, XF; Sun, JQ; Yang, H; Yin, C; Zhang, H | 1 |
| Ding, DY; Hou, RZ; Li, YC; Song, B; Sun, LB; Zhao, GJ | 1 |
| Hwang, IG; Kang, JH; Kang, WK; Kim, ST; Lee, HR; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, KW; Park, SH; Park, YS | 1 |
| Ahlgren, J; Akin, E; Bishop, C; Guebre-Xabiher, H; Kirkel, D; Patel, N; Schuck, S; Siegel, P; Siegel, R; Simmens, S | 1 |
| Dong, CX; Fu, JF; Li, XF; Ye, XY; Yuan, Y; Zhong, X | 1 |
| Bai, Y; Liang, J; Liu, H; Shen, L; Wang, J; Xu, J; Xu, N; Yang, L; Zhang, X | 1 |
| Boot, H; Cats, A; Jansen, EP; Nijkamp, J; Trip, AK; van Tinteren, H; Verheij, M | 1 |
| Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tokuyama, Y; Tsurushima, M; Uchiyama, K | 1 |
| Hara, Y; Minami, Y; Nakamura, T; Ueda, S | 1 |
| André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M | 1 |
| Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O | 1 |
| Boni, C; Clemens, M; Cohn, A; Dane, F; Ecstein-Fraisse, E; Follana, P; Harrison, M; Hitier, S; Massuti, B; Middleton, G; Moiseyenko, V; Pernot, S; Pimentel, FL; Prenen, H; Reichardt, P; Richards, DA; Rougier, P; Tabernero, J; Van Cutsem, E; Zaniboni, A | 1 |
| Choda, Y; Harano, M; Idani, H; Kanazawa, T; Matsukawa, H; Ninomiya, M; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Tokumoto, N | 1 |
| Doi, T; Nishida, T | 1 |
| Bang, YJ; Chen, JS; Choi, JH; Chung, HC; Chung, IJ; Ha, S; Ji, J; Kim, HH; Kim, HK; Kim, SW; Lee, JI; Lim, Y; Noh, SH; Park, SR; Shin, DB; Yang, HK; Yu, W | 1 |
| Do, IG; Kang, WK; Kim, KM; Kim, ST; Lee, J; Sohn, I | 1 |
| Alsina, M; Aranda, E; Cano, MT; Conde, V; Díaz-Rubio, E; Galán, M; García de Paredes, ML; López, C; Manzano, JL; Martínez Galán, J; Massutí, B; Pachón, V; Reboredo, M; Rivera, F; Salcedo, M; Sastre, J; Serrano, R; Valladares-Ayerbes, M; Yuste Izquierdo, AL | 1 |
| Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT | 1 |
| Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
| Cai, J; Li, T; Wu, B; Xu, Y; Zhao, G | 1 |
| Goodman, KA | 1 |
| Bae, JM; Choi, MG; Hong, ME; Jung, SH; Kang, WK; Kim, KM; Kim, S; Kim, ST; Lee, J; Lee, JH; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, I; Sohn, TS | 1 |
| Boonstra, JJ; Borel Rinkes, IH; Lolkema, MP; Los, M; Ruurda, JP; Schipper, ME; Siersema, PD; Ubink, I; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Voest, EE; Wiezer, MJ | 1 |
| Cai, Q; Chen, X; Ji, J; Liu, B; Shi, H; Yu, Y; Yuan, F; Zhang, J; Zhu, Z | 1 |
| Deng, W; Gao, J; Li, Y; Shen, L; Yuan, J; Zhou, J | 1 |
| Chung, IJ; Han, HS; Kang, SY; Kang, YK; Kim, JG; Lee, KH; Park, SR; Park, YS; Ryoo, BY; Ryu, MH; Song, EK; Yoo, C | 1 |
| Bang, YJ; Chen, Y; Doi, T; Lee, KW; Oh, DY; Park, SR; Shirao, K; Valota, O; Yang, L | 1 |
| Liang, N; Luo, H; Qiao, L; Wang, J; Xie, J; Xu, C; Zhang, J; Zhang, JX | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Doshi, S; Gisleskog, PO; Loh, E; Oliner, KS; Perez Ruixo, JJ; Zhang, Y; Zhu, M | 1 |
| Huang, CM; Li, P; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH | 1 |
| Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K | 1 |
| Adachi, S; Akagi, K; Dono, K; Hatano, H; Hirota, M; Hokonohara, K; Imamura, H; Iwazawa, T; Komori, T; Morita, S; Noda, T; Oshima, K; Takata, A; Tanida, T | 1 |
| Hatanaka, N; Honmyo, N; Inoue, M; Irei, T; Jeongho, M; Kurokawa, T; Odagiri, K; Shimizu, Y; Tanemura, M; Tominaga, H; Yamashita, S | 1 |
| Asaoka, T; Fujitani, K; Fukuda, Y; Haraguchi, N; Hirao, M; Ikeda, M; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Tsujinaka, T; Yamamoto, K | 1 |
| Aisu, Y; Ando, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N | 1 |
| Hanyu, T; Ichikawa, H; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nakano, M; Sakata, J; Shimada, Y; Tanaka, R; Wakai, T | 1 |
| Atsumi, Y; Fujikawa, Y; Hasegawa, S; Hayashi, T; Kanazawa, A; Masuda, M; Oshima, T; Rino, Y; Sato, T; Tamagawa, H; Tsuchida, K; Uchiyama, M; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Fisker, RV; Frøkjær, JB; Iyer, V; Kristensen, SR; Larsen, AC; Mortensen, PB; Møller, B; Thorlacius-Ussing, O; Yilmaz, MK | 1 |
| André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A | 1 |
| Huang, F; Lv, QZ; Shen, FM; Su, R; Xu, HB | 1 |
| Endo, S; Hiraoka, K; Kim, C; Konishi, K; Matsumoto, K; Nakagawa, T; Nishijima, J; Nishikawa, K; Okuyama, M; Takeda, K; Ueda, Y; Yamada, T | 1 |
| Bichev, D; Breithaupt, K; Daum, S; Dogan, Y; Schmidt, SC; Thuss-Patience, PC; Treese, C; von Winterfeld, M | 1 |
| Ahn, KS; Alharbi, SA; Arfuso, F; Chinnathambi, A; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Siveen, KS; Zayed, ME | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Berdel, WE; Brehler, AC; Hartmann, W; Kerkhoff, A; Kessler, T; Lenze, F; Palmes, D; Schliemann, C; Senninger, N; Ullerich, H; Wiebe, S | 1 |
| Dong, WG; He, AB; Luo, RF; Peng, XL; Song, J; Tang, Y; Zhang, JX | 1 |
| Li, YJ; Liu, X; Qin, ZF; Shi, J; Sun, YW; Wei, PK; Xiu, LJ; Yan, B; Zhang, YC; Zhou, YQ | 1 |
| Chu, Y; Feng, Y; Li, W; Liu, T; Luo, F; Qian, J; Wang, Y; Yang, J; Yu, Y; Zhang, D; Zhang, W; Zhao, N; Zheng, X | 1 |
| Chen, MW; Huang, HQ; Huang, JJ; Jiang, DK; Lu, DC; Wu, FL; Yang, X; Ying, YP; Zeng, HY; Zhou, AM; Zhou, J | 1 |
| Li, R; Li, Y; Liu, Y; Qiao, X; Shi, G; Tan, B; Tian, Y; Wang, J; Xu, Q; Yang, P; Zhang, J; Zhao, Q | 1 |
| Calpena, R; Gallego, J; Lacueva, FJ; Martinez-Blasco, A; Mingol, F; Morcillo, MA; Moya, P; Orduña, A; Ruiz, JA; Sola-Vera, J | 1 |
| Hofheinz, RD; Lorenzen, S | 1 |
| Bao, Y; Fei, MY; Feng, WM; Guo, HH; Tang, CW | 1 |
| Brunetti, O; Caldarola, L; Dell'Endice, S; Mangia, A; Monti, M; Santini, D; Saragoni, L; Scarpi, E; Silvestris, N; Simone, G | 1 |
| Bu, Z; Fan, B; Ji, J; Li, S; Li, Z; Ren, H; Shan, F; Tang, L; Wu, A; Wu, X; Zhang, L; Zong, X | 1 |
| Skoropad, VY | 1 |
| Bronsert, P; Glatz, T; Hoeppner, J; Hopt, UT; Kulemann, B; Makowiec, F; Marjanovic, G; Schäfer, M; Sick, O; Zirlik, K | 1 |
| Chen, L; Cheng, HD; Cui, JX; Li, JY; Liu, SF; Lu, CR; Shen, WS; Xi, HQ | 1 |
| Ahn, YC; Bae, JM; Choi, MG; Kang, WK; Kim, S; Kim, ST; Lee, J; Lim, DH; Lim, HY; Nam, H; Park, JO; Park, SH; Park, YS; Sohn, TS; Yu, JI | 1 |
| Wu, JR; Zhou, XP; Zhu, B | 1 |
| Higashi, Y; Ishikawa, S; Kubota, H; Maruo, H; Nishiyama, R; Shoji, T; Suzuki, K | 1 |
| Ajani, JA; Elimova, E | 1 |
| Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K | 1 |
| Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
| Azmi, S; Fadavi, H; Ferdousi, M; Malik, I; Malik, RA; Mansoor, W; Marshall, A; Petropoulos, IN; Ponirakis, G; Tavakoli, M | 1 |
| Bang, YJ; Kim, TY; Oh, DY | 1 |
| Barucca, V; D'Antonio, C; Falcone, R; Marchetti, P; Milano, A; Onesti, CE; Palombi, L; Righini, R; Roberto, M; Romiti, A | 1 |
| Ahn, HK; Baek, MY; Cho, EK; Chung, M; Hong, J; Kim, HS; Kim, YS; Lee, JH; Lee, WK; Park, I; Park, J; Shin, DB; Sym, SJ | 1 |
| Cho, H; Hayashi, S; Kawabe, T; Makuuchi, Y; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Sato, T; Segami, K; Yoshikawa, T | 1 |
| Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Legdeur, MC; Meulendijks, D; Schellens, JH | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Beeker, A; Beerepoot, LV; Beijnen, JH; Boers, JE; Boot, H; Cats, A; de Groot, JW; de Jong, RS; Goey, SH; Kuiper, M; Los, M; Meulendijks, D; Polee, MB; Portielje, JE; Schellens, JH; Sikorska, K; Tesselaar, ME; Vanhoutvin, SA | 1 |
| Gan, P; Liu, Q; Yao, Q; Zha, Y | 1 |
| Hu, YF; Li, FP; Li, GX; Li, TT; Lin, T; Liu, H; Mou, TY; Yu, J; Zheng, L | 1 |
| He, Q; Li, G; Li, Y; Ma, L | 1 |
| Cao, Y; Gao, J; Gong, J; Li, Y; Lu, Z; Shen, L; Zhang, Q | 1 |
| Bridgewater, J; Cunningham, D; Grenader, T; Oates, J; Peckitt, C; Starling, N; Waddell, T | 1 |
| Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J | 1 |
| Asai, K; Baba, M; Hiratsuka, M; Katsuyama, S; Murata, M; Saso, K; Sawami, H; Takahashi, H; Takayama, O; Tanaka, N; Yagi, T; Yamada, M; Yamamoto, M | 1 |
| Asakawa, A; Endo, T; Hasegawa, K; Kamiya, A; Kaneko, J; Kondo, I; Maejima, S; Takatsuno, Y | 1 |
| Chao, Y; Chen, LT; Chen, MH; Chen, YC; Hsiao, CF; Li, CP; Lin, J; Liu, TW; Shan, YS | 1 |
| Ao, L; Cai, H; Guan, Q; Guo, Z; Hong, G; Li, H; Li, J; Li, M; Li, X; Lin, X; Tong, M; Yang, D; Yang, S; Zheng, W | 1 |
| Bai, L; Bai, Y; Bi, F; Cheng, Y; Fan, Q; Gong, J; Liu, T; Liu, W; Qin, S; Shen, L; Wang, J; Wang, L; Xu, N | 1 |
| Cooray, P; Ferraro, DA; Ganju, V; Gebski, V; Hall, M; Pavlakis, N; Price, TJ; Shannon, JA; Sjoquist, KM; Strickland, A; Tebbutt, NC; Underhill, C; Varma, SC; Veillard, AS; Wong, N; Young, R | 1 |
| Boesveldt, S; de Vries, YC; Helmich, E; Karsten, MD; van Laarhoven, HW; Winkels, RM | 1 |
| Beeker, A; Beerepoot, LV; Beijnen, JH; Boers, JE; Cats, A; de Groot, JW; de Jong, RS; Goey, SH; Grootscholten, C; Kuiper, M; Los, M; Meulendijks, D; Pluim, D; Polee, MB; Portielje, JE; Schellens, JH; Sikorska, K; Tesselaar, ME; Vanhoutvin, SA | 1 |
| Ahn, S; Kang, WK; Kim, KM; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Jung, SH; Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Hwang, SH; Kim, SG | 1 |
| Kang, YK; Lee, CW; Na, YS; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Caruso, R; D'Andrea, V; Diaz, E; Duran, H; Fabra, I; Ferri, V; Ferronetti, A; Ielpo, B; Malave, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Liu, J; Ma, S; Zhu, L | 1 |
| Bu, ZD; Ji, JF; Li, ZY; Ren, H; Tang, L; Wu, AW; Yuan, P | 1 |
| Briner, C; Gladkov, O; Hsieh, RK; Kaneko, T; Koch, KM; LaBonte, MJ; Lee, WP; Lenz, HJ; Nagarwala, YM; Pishvaian, MJ; Rha, SY; Sakaeva, D; Urba, SG; Wilson, PM; Yang, D; Zhang, W | 1 |
| Arshad, A; Bowrey, DJ; Calder, PC; Dennison, AR; Eltweri, AM; Fisk, HL; Thomas, AL | 1 |
| Choe, AR; Choi, JE; Lee, KE; Nam, EM; Park, H; Yoon, SE | 1 |
| Lu, M; Wang, J; Wang, T | 1 |
| Abramovich, A; Amit, L; Brenner, B; Gordon, N; Idelevich, E; Kundel, Y; Medalia, G; Purim, O; Sadeh Gonik, U; Sarfaty, M; Sulkes, A | 1 |
| Arbea, L; Cano, D; Ceniceros, L; Chopitea, A; Diaz-Gonzalez, JA; Hernandez, JL; Iragorri, Y; Legaspi, J; Martin-Romano, P; Martínez-Regueira, F; Ponz-Sarvise, M; Rodríguez, J; Sola, JJ; Subtil, JC | 1 |
| Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
| Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, S; Yu, YY; Zhao, NQ; Zhuang, RY | 1 |
| Chin, M; Hagiwara, M; Hashizume, E; Honma, S; Horii, S; Takahashi, H; Takahashi, R; Takaya, K | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Mihara, H; Miura, Y; Nakada, N; Nanjo, S; Nishino, T; Sugiyama, T; Takagi, H; Yoshita, H | 1 |
| Afenjar, K; Bang, YJ; Chu, MP; Chua, N; Hecht, JR; Hiller, JP; Hoff, PM; Houe, V; Huang, YJ; Khan-Wasti, S; King, K; Koski, S; Mulder, K; Qin, S; Sawyer, MB; Scarfe, A; Slamon, D; Sobrero, A; Spratlin, J; Wainberg, ZA | 1 |
| Kitamura, S; Kuga, Y; Nishida, T; Okanobu, H; Sakimoto, H | 1 |
| Boku, N; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishimura, T; Okita, N; Shimada, Y; Takashima, A; Yamada, Y | 1 |
| Doshi, S; Hoang, T; Kasichayanula, S; Kuchimanchi, M; Zhang, Y; Zhu, M | 1 |
| Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP | 1 |
| Beijnen, JH; Cats, A; Deenen, MJ; Joerger, M; Meulendijks, D; Rozeman, EA; Schellens, JHM; Sikorska, K | 1 |
| Endo, S; Fujita, I; Horii, J; Matsueda, K; Murakami, T; Sakata, M; Toyokawa, T; Ueda, Y | 1 |
| Ci-Ren, BS; Duo-Ji, MM; Long, ZW; Luo, DL; Zhang, XH | 1 |
| Banavali, S; Chougule, A; Joshi, A; Noronha, V; Patil, VM; Prabhash, K | 1 |
| Ishii, T; Katayama, T; Kawasaki, Y; Okubo, Y; Otsuru, M; Senba, S; Shinozaki, K; Tono, T; Yasuda, S | 1 |
| Ajiki, T; Fujita, S; Ikeda, T; Ishiyama, S; Kobayashi, S; Kondo, N; Miyazaki, K; Sato, M; Shirasaki, K; Tsuchihara, K; Yamauchi, J; Yasuta, S | 1 |
| Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Uemura, M; Yamamoto, K | 1 |
| Akiyama, Y; Egawa, C; Inatome, J; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Kaito, A; Kinoshita, T; Nishida, T; Shibasaki, H; Shitara, K | 1 |
| Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I | 1 |
| Cheng, A; Kwok, TY; Lee, VW; Leung, PY; Ng, WT; Yao, R; Yip, EY; Zhou, KR | 1 |
| Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Mai, S; Möhler, M; Post, S; Schwarzbach, M; Staiger, W; Wenz, F; Willeke, F | 1 |
| Barone, C; Pozzo, C | 1 |
| Aberer, E; Gerger, A; Kränke, B; Salmhofer, W; Weger, W | 1 |
| Baek, JH; Chang, HM; Kang, HJ; Kang, WK; Kang, YK; Kim, JG; Kim, TW; Lee, JL; Lee, KH; Min, YJ; Park, SR; Ryoo, BY; Ryu, MH; Shin, DB; Zang, DY | 1 |
| Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I | 1 |
| Hyodo, I; Koizumi, W; Kojima, H; Okayasu, I; Sakamoto, J | 1 |
| Hang, X; Liu, C; Sun, Q; Wang, D; Zhong, B | 1 |
| Hang, X; Ma, S; Sun, Q; Wang, D; Yang, Y; Ying, JE; Yong, D; Zhang, Y; Zhong, B; Zhong, H | 1 |
| Chau, I; Cunningham, D; Okines, A | 2 |
| Bekaii-Saab, T; Haghighat, P | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Kim, GH; Seol, YM; Shin, HJ; Song, GA; Song, MK | 1 |
| Saif, MW; Sandoval, A | 1 |
| Abakar-Mahamat, A; Baize, N; Berthier, F; Caroli-Bosc, FX; Mounier, N | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA | 1 |
| Chen, J; Forster, G; Guan, Z; Kang, WK; Kang, YK; Khasanov, R; Lichinitser, M; McCloud, PI; Philco-Salas, M; Santamaria, J; Shin, DB; Suarez, T; Wang, J; Xiong, J; Zheng, L | 1 |
| Chau, I; Cunningham, D; Harper, P; Hawkins, R; Hickish, T; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Seymour, M | 1 |
| Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y | 1 |
| Jensen, BY; Jensen, HA; Larsen, O; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Baselga, J; Benson, M; Cunningham, D; Hill, A; Kurek, R; Lüpfert, C; Oates, J; Rao, S; Starling, N; Wotherspoon, A | 1 |
| Casaretti, R; Comella, P; de Portu, S; Franco, L; Menditto, E | 1 |
| AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA | 1 |
| Coxon, F; Cunningham, D; Daniel, F; Iveson, T; Middleton, G; Nicolson, M; Norman, AR; Oates, J; Rao, S; Starling, N | 2 |
| Lau, SC; Shibata, SI | 1 |
| Boda-Heggemann, J; Hermes, P; Hieber, U; Hochhaus, A; Hofheinz, RD; Lohr, F; Mai, SK; Massner, B; Mennemeyer, P; Post, S; Weiss, C; Wenz, F; Wertz, H | 1 |
| Allum, W; Ashley, S; Benson, M; Brown, G; Chau, I; Cunningham, D; Oates, J; Okines, A; Riddell, A; Starling, N; Stavridi, F; Thomas, J; Thompson, J; Wotherspoon, A | 1 |
| Ashley, S; Chau, I; Cunningham, D | 1 |
| Cunningham, D; Kang, YK; McCloud, P; Norman, AR; Okines, AFC | 1 |
| Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR | 1 |
| Dong, N; Jiang, W; Li, H; Liu, Z; Wang, M; Xu, X | 1 |
| Daum, S; Ebert, MP; Flieger, D; Galle, PR; Geissler, M; Hoehler, T; Kanzler, S; Moehler, M; Raedle, J; Seufferlein, T | 1 |
| Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD | 1 |
| Dong, NN; Liu, ZF; Wang, MY; Zhang, Q | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, J; Mroue, RM; Nasr, FL; Younes, FC | 1 |
| Boot, H; Cats, A; Dubbelman, R; Jansen, EPM; Verheij, M | 1 |
| Saif, MW; Shi, N; Zelt, S | 1 |
| Hang, M; Hang, X; Li, M; Mao, W; Sun, Q; Xu, W; Zhang, J | 1 |
| Teng, KY; Xu, RH | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Caponi, S; Falcone, A; Fornaro, L; Ginocchi, L; Loupakis, F; Masi, G; Vasile, E | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Kang, YK; Ryu, MH | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, C; Kim, TW; Lee, JL; Lim, HY; Park, YS; Ryoo, BY; Ryu, MH | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yun, J | 1 |
| Cummins, MM; Ganju, V; Gebski, V; Gibbs, D; Sourjina, T; Stockler, M; Strickland, A; Tebbutt, NC; Van Hazel, G; Zalcberg, J | 1 |
| Jørgensen, JT | 1 |
| Ashley, S; Cunningham, D; Okines, AF | 1 |
| Aneiros-Cachaza, J; Aneiros-Fernandez, J; Arias-Santiago, S; Escobar Gómez-Villalva, F; Husein-ElAhmed, H; Nicolae, A; O'Valle Ravassa, F | 1 |
| Abali, H; Disel, U; Gürkut, O; Kaleağasi, H; Mertsoylu, H; Ozyilkan, O; Saif, MW | 1 |
| He, BF; Jia, YZ; Liao, H; Min, N; Zhang, LS | 1 |
| Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG | 1 |
| Chen, XQ; Li, FH; Li, YH; Luo, HY; Qiu, MZ; Wang, F; Xu, RH; Zhou, ZW | 1 |
| Bakker, B; Boot, H; Cats, A; Dikken, JL; Hartgrink, HH; Jansen, EP; Kranenbarg, EM; Peeters, KC; Putter, H; van de Velde, CJ; Verheij, M | 1 |
| Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H | 1 |
| Feng, M; Qiu, F; Xiang, XJ; Xiong, JP; Yu, F; Zhan, ZY; Zhang, L | 1 |
| Andersen, M; Jensen, HA; Pfeiffer, P; Schønnemann, KR; Vestermark, LW; Yilmaz, M | 1 |
| Emiliani, A; Losanno, T; Manna, G; Seminara, P | 1 |
| Archer, C; Beadman, C; Cunningham, D; Gilligan, D; Kurek, R; Oates, J; Rao, S; Ruhstaller, T; Starling, N; Sumpter, K; Valladares-Ayerbes, M; Wilke, H | 1 |
| Aggarwal, S; Goel, G; Jauhri, M; Negi, A | 1 |
| Allali, M; Bergmann, U; Kummer, G; Riebeling, J; Schultheis, B; Sendler, A; Sendler, U; Strumberg, D; Tannapfel, A | 1 |
| Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Tham, CK; Toh, HC; Wang, ML | 1 |
| Ashley, SE; Chau, I; Chua, YJ; Cunningham, D; Oates, J; Okines, AF; Saffery, C; Turner, A; Webb, J | 1 |
| de Jongh, FE; Eskens, FA; Konings, IR; Sleijfer, S; van der Gaast, A; van der Wijk, LJ | 1 |
| Aprile, G; Bang, YJ; Chung, HC; Feyereislova, A; Hill, J; Kang, YK; Kulikov, E; Lehle, M; Lordick, F; Ohtsu, A; Omuro, Y; Rüschoff, J; Satoh, T; Sawaki, A; Shen, L; Van Cutsem, E | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH | 1 |
| Chang, HM; Choi, YH; Kang, BW; Kang, YK; Kim, C; Kim, TW; Lee, JL; Ryu, MH | 1 |
| Bernal, P; Byrd, J; Malik, I | 1 |
| Andersen, M; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Bai, CM; Guan, M; Zhang, L; Zhao, L | 1 |
| Eastwood, A; Norman, G; Peura, P; Rice, S; Sculpher, M; Soares, M; Suh, D; Wright, K | 1 |
| Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Güzel, E; Sentürk, S | 1 |
| Fujita, T | 1 |
| Dong, CM; Kang, MF; Liu, Y; Luo, MQ | 1 |
| Jang, JS; Kim, HJ; Kim, KH; Kim, MC; Kim, SH; Kwon, HC; Kwon, KA; Lee, HS; Lee, S; Oh, SY | 1 |
| Bouché, O; Penault-Llorca, F | 1 |
| He, S; Hong, L; Niu, D; Niu, L; Shen, J | 1 |
| Boc, M; Hlebanja, Z; Ocvirk, J; Reberšek, M; Skof, E | 1 |
| Arima, N; Shigaki, N; Sugita, H; Suzuki, S; Yamashita, H; Yokoyama, S | 1 |
| Cassidy, J; Cunningham, D; Gilberg, F; Hoff, P; Kang, Y; Saini, JP; Saltz, L; Twelves, C; Van Cutsem, E | 1 |
| Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS | 1 |
| Chen, YB; Feng, XY; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ; Zhou, ZW | 1 |
| Chen, DY; Qi, Q; Zhao, WY | 1 |
| Gao, J; Li, YY; Lu, M; Shen, L; Yu, JW | 1 |
| Danso-Appiah, A; Eastwood, A; Norman, G; Palmer, S; Rice, S; Spackman, E; Stirk, L; Suh, D | 1 |
| Ajani, JA; Blum, M; Suzuki, A | 1 |
| Cui, YH; Li, W; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, ZM; Yu, YY | 1 |
| Gao, MQ; Huang, AM; Zhuo, LJ | 1 |
| Bichev, D; Blau, I; Breithaupt, K; Dogan, Y; Grieser, C; Grothoff, M; Kretzschmar, A; Reichardt, P; Rothmann, F; Schwaner, I; Thuss-Patience, PC | 1 |
| Boot, H; Cats, A; Dikken, JL; Jansen, EP; Lind, PA; Maurits Swellengrebel, HA; Putter, H; van de Velde, CJ; van Grieken, NC; van Sandick, JW; Verheij, M | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Deftereos, S; Dimopoulos, P; Kakolyris, S; Karanikas, M; Karayiannakis, A; Michailidis, P; Tentes, A; Xenidis, N | 1 |
| Kang, YK; Langer, B; Lim, HY; Ohtsu, A; Park, SR; Rha, SY; Sawaki, A; Shah, MA; Starnawski, M; Van Cutsem, E; Wu, J; Yamada, Y | 1 |
| Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y | 1 |
| Baglin, TP; Ford, H; Hardwick, RH; Peters, CJ; Rollins, KE; Safranek, PM | 1 |
| Ma, Y; Tang, L; Wang, HX; Xu, YC; Zhang, FC | 1 |
| Albouzidi, A; Ali, AA; Debbagh, A; Elkaoui, H; Errihani, H; Essaidi, I; Fetohi, M; Ichou, M; Kadiri, H; Mahi, M; Moussaid, Y; Oukabli, M; Sbitti, Y; Slimani, K | 1 |
| He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH | 1 |
| Boku, N; Hamamoto, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, T; Tamura, T | 1 |
| Bang, YJ | 1 |
| Ajani, JA; Beddar, AS; Briere, TM; Chakravarty, T; Crane, CH; Das, P; Delclos, ME; Krishnan, S; Mansfield, PF; Mok, H; Reed, VK | 1 |
| Abe, T; Baba, E; Boku, N; Hamamoto, Y; Hatake, K; Miyata, Y; Nishina, T; Ohashi, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamaguchi, K | 1 |
| Ahn, YC; Bae, JM; Choi, MG; Jung, SH; Kang, WK; Kim, KM; Kim, S; Lee, J; Lim, DH; Lim, HY; Noh, JH; Park, CK; Park, JO; Park, SH; Park, YS; Sohn, I; Sohn, TS | 1 |
| Bang, YJ; Button, P; Cho, JY; Chung, HC; Ji, J; Kim, YH; Kim, YW; Lee, KH; Lee, KW; Mok, YJ; Noh, SH; Noh, SI; Park, YK; Sirzén, F; Yang, HK; Yeh, TS | 1 |
| Chung, HC; Jeung, HC; Jung, I; Kim, GM; Kim, HS; Lee, KH; Nam, BH; Rha, SY | 1 |
| Alidoosti, A; Ameri, A; Aref, S; Fadavi, P; Moghadam, MM; Rasouli, HA; Sheybani, KM; Tabatabaiefar, M; Taslimi, F | 1 |
| Feng, M; Qiu, F; Xiang, XJ; Xiong, JP; Yan, J; Yu, F; Zhan, ZY; Zhang, L; Zhao, JG | 1 |
| Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Fong, CW; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Tan, P | 1 |
| Kondo, C; Matsuo, K; Mizota, A; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
| Hochster, HS; Levinson, B; Muggia, F; Newman, E; Ryan, T; Wu, J | 1 |
| Bains, S; Madhavarao, B; Mutyala, V; Patil, C | 1 |
| Agolli, L; Bracci, S; De Sanctis, V; Enrici, RM; Minniti, G; Monaco, F; Osti, MF; Tubin, S | 1 |
| Kondo, C; Matsuo, K; Muro, K; Niwa, Y; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
| Buonadonna, A; Corona, G; Frustaci, S; Lo Re, G; Miolo, G; Tabaro, G; Toffoli, G; Torrisi, E; Tumolo, S; Turchet, E | 1 |
| Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC | 1 |
| Arasaradnam, RP; Borman, RA; Goodyear, SJ; James, S; Jarvie, EM; Nwokolo, CU; Sanger, GJ; Snead, D; Sung, EZ | 1 |
| Gao, J; Li, Y; Lu, Z; Shen, L; Yu, J | 1 |
| Abe, T; Baba, E; Boku, N; Chin, K; Doi, T; Hamamoto, Y; Koizumi, W; Komatsu, Y; Miyata, Y; Nishina, T; Ohtsu, A; Omuro, Y; Saji, S; Sato, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamada, Y; Yamaguchi, K | 1 |
| Kobayashi, M; Kodera, Y; Morita, S; Sakamoto, J; Shitara, K; Tsuburaya, A; Yamaguchi, K; Yoshida, K; Yoshikawa, T; Yoshino, S | 1 |
| Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R | 1 |
| Baek, JH; Cho, SH; Choi, YH; Chung, IJ; Hong, YS; Jeung, HC; Kang, HJ; Kim, BS; Kim, JS; Nam, SH; Oh, SC; Song, EK; Yang, SH; Yim, CY | 1 |
| Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I | 1 |
| Adachi, T; Goto, A; Itoh, M; Kanno, S; Kondo, Y; Mitsuhashi, K; Shinomura, Y; Suzuki, T; Wakasugi, H; Yabana, T | 1 |
| Allum, WH; Blazeby, JM; Coxon, F; Cunningham, D; Evans, L; Falk, S; Ford, D; Griffin, M; Hall, M; Iveson, TJ; Langley, RE; Middleton, GW; Okines, AF; Petty, RD; Plummer, C; Seymour, M; Slater, S; Smith, D; Stenning, SP; Stevenson, L; Thompson, LC; Waters, J | 1 |
| Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD | 1 |
| Chen, X; Dai, C; Zhao, C | 1 |
| Becker, K; Belle, S; Ebert, MP; Hofheinz, R; Krause, A; Mayr, M; Röcken, C; Schmid, RM; Schulte, N | 1 |
| Hamamoto, Y; Nishi, T; Onodera, K; Uemoto, J; Warita, E; Yamanaka, Y | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, X; Ye, LH; Zhan, YP | 1 |
| Gao, J; He, Q; Hua, D; Li, Y; Mao, Y; Shen, L | 1 |
| Aono, T; Deguchi, K; Deguchi, T; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Nomura, M; Takagi, M; Tamagawa, H; Tanaka, Y; Umeda, S; Yoshida, H | 1 |
| Chang, SL; Chen, YN; Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Zhang, ZD; Zhao, Q; Zhao, XF | 1 |
| Chen, Y; Feng, Y; Li, Q; Liu, TS; Wang, ZM; Zhuang, RY | 1 |
| Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M | 1 |
| Ahn, JH; Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Yook, JH | 1 |
| Koizumi, W; Saigenji, K; Sakata, Y; Taguchi, T; Terashima, M; Ujiie, S | 1 |
| Rich, TA; Shepard, R | 1 |
| Chung, JH; Kim, SA; Lee, HJ; Park, YH; Ryoo, BY | 1 |
| Choi, SJ; Kim, HT; Park, YH; Ryoo, BY | 1 |
| Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY | 1 |
| Hong, YS; Kang, JH; Kim, GY; Lee, KS; Lee, MA; Shim, KH; Woo, IS | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH | 2 |
| Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ | 1 |
| Bae, JM; Choi, IJ; Choi, JY; Chun, JH; Hwangbo, B; Kim, CG; Kim, HK; Kim, YW; Lee, HG; Lee, JS; Park, SR; Ryu, KW | 1 |
| Chong, G; Cunningham, D | 1 |
| Cunningham, D; Harper-Wynne, C; Hickish, T; Hill, M; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Rao, S; Sumpter, K; Tebbutt, N; Ward, C | 1 |
| Baek, JH; Jung, HY; Kim, DH; Kim, JG; Kim, TB; Lee, KB; Park, JY; Sohn, SK; Sung, WJ; Yu, W | 1 |
| Bang, SM; Cho, EK; Im, SA; Lee, JH; Lee, SN; Lee, WK; Park, DK; Park, SH; Park, YH; Shin, DB | 1 |
| Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY | 1 |
| Andronikidis, I; Bitzilekis, D; Eleftheriadis, D; Eleftheriadis, N; Kouloulias, V; Papaloukas, C; Pistevou-Gompaki, K | 1 |
| Chin, K; Hyodo, I; Koizumi, W; Kojima, H; Kondo, K; Sakamoto, J; Terashima, M; Tsujinaka, T; Yamamura, Y | 1 |
| Choi, Y; Hur, WJ; Jung, GJ; Kim, HJ; Kim, JS; Kim, MC; Kim, SH; Kwon, HC; Lee, HS; Lee, JH | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK | 1 |
| Kim, BS; Park, YH; Ryoo, BY; Yang, SH | 1 |
| Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C | 1 |
| Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W | 1 |
| Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J | 1 |
| Ajani, J | 1 |
| Aurilio, G; Carlomagno, C; Catalano, G; Ciardiello, F; De Placido, S; De Vita, F; Galizia, G; Lieto, E; Martinelli, E; Orditura, M; Vecchione, L | 1 |
| Hwang, SJ; Kim, BS; Kim, GJ; Lee, SD; Nam, SH; Park, JW; Sin, CH | 1 |
| Chang, HM; Jung, JY; Kang, YK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Ryu, MH; Song, JH; Song, JS; Yook, JH | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Kim, WK; Lee, JL; Lee, JS; Lee, SS; Ryu, MH | 1 |
| Dhillon, S; Scott, LJ | 1 |
| Kang, YK | 1 |
| Holcombe, RF; Ou, SH | 1 |
| López-Brea, MF; Rivera, F; Vega-Villegas, ME | 1 |
| Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ; Yoo, NC | 1 |
| Doorn, L; Eskens, FA; van der Gaast, A; van Gameren, EC; van Meerten, E | 1 |
| Dupont, J; Jensen, BV; Jensen, HA; Pfeiffer, P | 1 |
| Barceló, R; Carrera, S; Fernández, R; López-Vivanco, G; Martínez-Bueno, A; Muñoz, A; Rubio, I; Viteri, A | 1 |
| Choi, IK; Chun, HJ; Jeen, YT; Kim, JS; Kim, YH; Mok, YJ; Oh, SC; Park, SS; Seo, JH; Shin, SW; Sung, HJ; Sur, HY | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Park, YH; Ryoo, BY; Ryu, MH; Shin, DB; Yang, SH; Yuh, YJ | 1 |
| Bilancia, D; Dinota, A; Germano, D; Manzione, L; Reggiardo, G; Romano, R; Rosati, G | 1 |
| Sharma, SP | 1 |
| Bartelink, H; Boot, H; Cats, A; Crosby, TD; Dubbelman, R; Jansen, EP; Saunders, MP; Verheij, M | 1 |
| Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H | 1 |
| Kondoh, K; Mori, K; Sawada, N | 1 |
| Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Verheij, M | 1 |
| Akerman, P; Berkenblit, A; Chauhan, B; Cruff, D; Evans, D; Habr, F; Harrington, D; Iannitti, D; Kennedy, T; Maia-Acuna, C; Miner, T; Safran, H; Sears, D; Stuart, K | 1 |
| Ajani, JA; Cen, P | 1 |
| A-Manaf, A; Foo, KF; Koo, WH; Lim, WT; Quek, R; Toh, HC | 1 |
| Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G | 1 |
| Cho, SJ; Choi, IJ; Han, HS; Kim, CG; Kim, NK; Kim, SY; Kook, MC; Lee, JR; Lee, JS; Park, SR; Park, YI | 1 |
| Cascinu, S | 1 |
| Barbuzza, O; Guarneri, B; Guarneri, F; Vaccaro, M | 1 |
| Kang, YK; Lee, JL | 1 |
| Ajani, JA | 1 |
| Saeki, T; Takashima, S | 1 |
| Lewis, NL; Meropol, NJ | 1 |
| Koizumi, W | 1 |
58 review(s) available for capecitabine and Stomach Neoplasms
| Article | Year |
|---|---|
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoplasms; Stomach Neoplasms | 2022 |
Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Male; Neoplasms; Proton Pump Inhibitors; Retrospective Studies; Stomach Neoplasms | 2020 |
[Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Perioperative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2020 |
The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Disease-Free Survival; Drug Combinations; Humans; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2020 |
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy A case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Esophagectomy; Gastrectomy; Hepatic Infarction; Humans; Liver; Male; Necrosis; Oxaliplatin; Stomach Neoplasms | 2020 |
Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2021 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Neoplasm; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lapatinib; Oxaliplatin; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2021 |
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Platinum Compounds; Ramucirumab; Stomach Neoplasms; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Proportional Hazards Models; Publication Bias; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Oxaloacetates; Stomach Neoplasms | 2018 |
Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Hand-Foot Syndrome; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Treatment Outcome; Young Adult | 2018 |
Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drugs, Chinese Herbal; Fluorouracil; Humans; Network Meta-Analysis; Oxaloacetates; Stomach Neoplasms | 2018 |
[A Case of Gastric Carcinoma with Peritoneal Dissemination Treated with Curative Resection Following Trastuzumab plus Capecitabine plus Cisplatin Combined Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Humans; Male; Peritoneal Neoplasms; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2018 |
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Lymph Node Excision; Network Meta-Analysis; Oxaloacetates; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur | 2018 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2013 |
Capecitabine in the treatment of esophageal and gastric cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms | 2013 |
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Humans; Neoplasm Staging; Odds Ratio; Oxonic Acid; Publication Bias; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2013 |
[Pharmacogenomics of the first-line treatment for gastric cancer: advances in the identification of genomic biomarkers for clinical response to chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomarkers; Biotransformation; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Enzymes; Ethnicity; Fluorouracil; Gastrectomy; Humans; Mexico; Molecular Targeted Therapy; Organoplatinum Compounds; Oxonic Acid; Patient Selection; Pharmacogenetics; Precision Medicine; Prodrugs; Stomach Neoplasms; Tegafur | 2014 |
Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Odds Ratio; Organoplatinum Compounds; Oxaloacetates; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Drug Combinations; Hand-Foot Syndrome; Humans; Odds Ratio; Oxonic Acid; Risk Factors; Stomach Neoplasms; Survival Analysis; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2015 |
A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Topics: Capecitabine; China; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Oxonic Acid; Severity of Illness Index; Stomach Neoplasms; Tegafur | 2015 |
Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Neoplasm Metastasis; Ramucirumab; Stomach Neoplasms | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cell Differentiation; Chemotherapy, Adjuvant; Endosonography; Gastrectomy; Gastric Bypass; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Capecitabine for the treatment of gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2015 |
Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Middle Aged; Network Meta-Analysis; Oxonic Acid; Pyruvates; Stomach Neoplasms; Tegafur | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Two cases of unresectable advanced HER2-positive gastric cancer perforation during chemotherapy with trastuzumab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Female; Humans; Intestinal Perforation; Male; Receptor, ErbB-2; Stomach; Stomach Diseases; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2017 |
Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer.
Topics: Administration, Metronomic; Antineoplastic Agents; Capecitabine; Cyclophosphamide; Esophageal Neoplasms; Evidence-Based Medicine; Humans; Paclitaxel; Patient Selection; Stomach Neoplasms; Treatment Outcome | 2017 |
[A Case of Advanced Gastric Cancer with Extensive Lymph Node Metastases Treated by Capecitabine plus Cisplatin plus Trastuzumab Chemotherapy,Followed by Conversion Surgery].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Female; Gastrectomy; Humans; Lymphatic Metastasis; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2016 |
Capecitabine in gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Patient Acceptance of Health Care; Protein Binding; Stomach Neoplasms | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; ErbB Receptors; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2009 |
Emerging role of capecitabine in gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Stomach Neoplasms | 2009 |
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome; Young Adult | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Capecitabine for the treatment of advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Palliative Care; Prodrugs; Stomach Neoplasms | 2010 |
[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Contraindications; Deoxycytidine; Esophagogastric Junction; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization; Paraffin Embedding; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2011 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.
Topics: Antineoplastic Agents; Asian People; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasm Staging; Stomach Neoplasms; White People | 2012 |
Capecitabine in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Stomach Neoplasms; Treatment Outcome | 2011 |
Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Deoxycytidine; Endoscopy, Digestive System; Esophagostomy; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Stomach Neoplasms; Sulfonamides | 2003 |
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Esophageal Diseases; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms | 2006 |
Capecitabine: in advanced gastric or oesophagogastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Treatment Outcome | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
Capecitabine in advanced gastric cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms | 2007 |
Capecitabine in the treatment of advanced gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2008 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Stomach Neoplasms | 1999 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2000 |
[Capecitabine (Ro09-1978) for therapy of advanced and recurrent gastric cancer].
Topics: Administration, Oral; Animals; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Design; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Oxidoreductases; Stomach Neoplasms; Thymidine Phosphorylase; Treatment Outcome | 2001 |
213 trial(s) available for capecitabine and Stomach Neoplasms
| Article | Year |
|---|---|
XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Liver Neoplasms; Oxaliplatin; Oxaloacetates; Prospective Studies; Quality of Life; Stomach Neoplasms | 2022 |
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Epirubicin; Fluorouracil; Humans; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2022 |
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Gastrectomy; Humans; Neoplasm Recurrence, Local; Oxaliplatin; Stomach Neoplasms | 2022 |
Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Oxaliplatin; Phosphatidylinositol 3-Kinases; Stomach Neoplasms | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Peritoneal Neoplasms; Stomach Neoplasms | 2023 |
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Humans; Sorafenib; Stomach Neoplasms; Treatment Outcome | 2023 |
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Oxaliplatin; Peritoneal Neoplasms; Stomach Neoplasms | 2023 |
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with breast, colorectal or gastric cancer under fed condition: A multicentric, randomized, open-label, single-dose, two-period, two-way crossover clinical trial.
Topics: Area Under Curve; Capecitabine; China; Colorectal Neoplasms; Cross-Over Studies; East Asian People; Fasting; Humans; Stomach Neoplasms; Tablets; Therapeutic Equivalency | 2023 |
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Fluorouracil; Humans; Molecular Chaperones; Neoplasm Recurrence, Local; Oxaliplatin; Stomach Neoplasms; Tumor Suppressor Proteins | 2023 |
Study of Efficacy and Toxicity of Capecitabine Maintenance After Response to Docetaxel, Cisplatin, and 5-Fluracil-Based Chemotherapy in Advanced Carcinoma Stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Docetaxel; Fluorouracil; Humans; Prospective Studies; Stomach Neoplasms | 2023 |
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Claudins; Esophagogastric Junction; Humans; Oxaliplatin; Stomach Neoplasms | 2023 |
SPOTlight on GLOW.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Claudins; Esophageal Neoplasms; Humans; Receptor, ErbB-2; Stomach Neoplasms | 2023 |
Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Gastrectomy; Humans; Immunotherapy; Lymph Nodes; Neoplasm Staging; Prospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Capecitabine; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Stomach Neoplasms | 2023 |
Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.
Topics: Acetylcysteine; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Double-Blind Method; Female; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Oxaliplatin; Oxaloacetates; Stomach Neoplasms | 2020 |
[A Phase Ⅱ Study of Systemic Chemotherapy with Capecitabine and Cisplatin Followed by Surgery for Advanced Gastric Cancer with Extensive Lymph Node Metastasis(OGSG1401)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Humans; Lymph Nodes; Lymphatic Metastasis; Stomach Neoplasms | 2020 |
The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Confidence Intervals; Disease-Free Survival; Drug Combinations; Female; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxaloacetates; Oxonic Acid; Prognosis; ROC Curve; Sample Size; Stomach Neoplasms; Tegafur | 2020 |
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Oxaliplatin; Prognosis; Stomach Neoplasms; Survival Rate | 2021 |
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Stomach Neoplasms | 2021 |
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Oxaliplatin; Perioperative Care; Receptor, ErbB-2; Spain; Stomach Neoplasms; Time Factors; Trastuzumab | 2021 |
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Claudins; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Patient Reported Outcome Measures; Progression-Free Survival; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2021 |
A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Stomach Neoplasms; Survival Rate | 2021 |
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Oxaliplatin; Randomized Controlled Trials as Topic; Response Evaluation Criteria in Solid Tumors; Stomach Neoplasms; Treatment Outcome | 2021 |
A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Esophagogastric Junction; Female; Gastrectomy; Humans; Male; Middle Aged; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2021 |
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Frail Elderly; Humans; Male; Oxaliplatin; Quality of Life; Stomach Neoplasms | 2021 |
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Temozolomide; Treatment Outcome | 2021 |
A Pilot Study of Perioperative Cisplatin-Capecitabine Chemotherapy With Preoperative Chemoradiation for Resectable Gastric Cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Female; Gastrectomy; Humans; Male; Middle Aged; Pilot Projects; Preoperative Care; Prospective Studies; Radiotherapy Dosage; Stomach Neoplasms; Treatment Outcome; Young Adult | 2021 |
Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxaloacetates; Postoperative Period; Prospective Studies; Radiotherapy, Conformal; Stomach Neoplasms; Treatment Outcome | 2021 |
Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer.
Topics: Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Capecitabine; CD24 Antigen; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Stomach Neoplasms; Survival Rate; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2017 |
Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophagogastric Junction; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Ramucirumab; Stomach Neoplasms; Tegafur | 2018 |
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Postoperative Care; Preoperative Care; Stomach Neoplasms | 2017 |
A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Stomach Neoplasms | 2017 |
Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2017 |
A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cytochrome P-450 CYP2A6; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Oxonic Acid; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Random Allocation; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2018 |
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Combined Modality Therapy; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Panitumumab; Perioperative Care; Prognosis; Societies, Medical; Stomach Neoplasms; Survival Rate | 2018 |
Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; China; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Oxaliplatin; Republic of Korea; Stomach Neoplasms; Treatment Outcome | 2018 |
The Effect of Telephone-Based Follow-Up on Adherence, Efficacy, and Toxicity of Oral Capecitabine-Based Chemotherapy.
Topics: Adult; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Egypt; Female; Health Services; Humans; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Patient Acceptance of Health Care; Pharmacists; Prospective Studies; Stomach Neoplasms; Telephone | 2019 |
Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Laparoscopy; Male; Middle Aged; Oxaliplatin; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Single-Blind Method; Stomach Neoplasms; Treatment Outcome; Young Adult | 2018 |
miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Multigene Family; Oxaloacetates; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Long Noncoding; Stomach Neoplasms; Treatment Outcome; Young Adult | 2018 |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate | 2019 |
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Oxaliplatin; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Proliferation; Cytokines; Dietary Supplements; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fatty Acids, Omega-3; Feasibility Studies; Female; Fish Oils; Humans; Male; Middle Aged; Oxaliplatin; Palliative Care; Pilot Projects; Prospective Studies; Stomach Neoplasms; Treatment Outcome; Triglycerides | 2019 |
Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Capecitabine; Drug Combinations; Female; Follow-Up Studies; Humans; Lymphocytes; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Oxaloacetates; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Spain; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2019 |
Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial.
Topics: Adult; Aged; Asian People; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Male; Microsatellite Instability; Middle Aged; Prognosis; Proportional Hazards Models; Stomach Neoplasms | 2019 |
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Perioperative Period; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Stomach Neoplasms; Trastuzumab; Treatment Outcome; Young Adult | 2019 |
High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Cisplatin; ErbB Receptors; Female; Humans; Male; Middle Aged; Prevalence; Prognosis; Stomach Neoplasms; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2019 |
Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Clinical Protocols; Combined Modality Therapy; Epirubicin; Esophagogastric Junction; Gastrectomy; Humans; Quality Assurance, Health Care; Stomach; Stomach Neoplasms | 2019 |
A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Celecoxib; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2019 |
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2013 |
Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Prevalence; Radiotherapy, Conformal; Stomach Neoplasms; Survival Analysis; Survival Rate; Treatment Outcome | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex | 2013 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Protein Kinase Inhibitors; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophagogastric Junction; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2013 |
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Male; Middle Aged; Stomach Neoplasms; Vorinostat | 2014 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Vomiting | 2013 |
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Sirolimus; Stomach Neoplasms; Young Adult | 2013 |
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Treatment Outcome | 2013 |
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Stomach Neoplasms; Sunitinib | 2013 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
[Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Cell Cycle; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins p21(ras); Remission Induction; Stomach Neoplasms; Survival Rate; Survivin; Tumor Suppressor Protein p53 | 2013 |
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival Analysis | 2014 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Platinum; Pyrimidines; Stomach Neoplasms | 2013 |
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Young Adult | 2014 |
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
[Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Trastuzumab | 2014 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2014 |
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2015 |
Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; China; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
[Prospective multicentric phase III study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Fluorouracil; Germany; Humans; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prevalence; Risk Factors; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bevacizumab; Biological Availability; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Gastrectomy; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Stomach Neoplasms; Treatment Outcome | 2014 |
Quality of life in the trastuzumab for gastric cancer trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Humans; Quality of Life; Receptor, ErbB-2; Stomach Neoplasms; Surveys and Questionnaires; Trastuzumab | 2014 |
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2014 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Differentiation; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Preoperative Care; Prognosis; Retrospective Studies; Stomach Neoplasms; Tertiary Healthcare | 2014 |
Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Topics: Acyl Coenzyme A; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Simvastatin; Stomach Neoplasms; Treatment Outcome; Young Adult | 2014 |
Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cetuximab; Cisplatin; Deoxycytidine; ErbB Receptors; Esophagogastric Junction; Female; Fluorouracil; Gene Dosage; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Transforming Growth Factor alpha; Treatment Outcome; Young Adult | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Everolimus; Female; Genes, erbB-1; Genes, erbB-2; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Proto-Oncogene Proteins c-met; ROC Curve; Salvage Therapy; Sensitivity and Specificity; Sequence Analysis, RNA; Stomach Neoplasms | 2015 |
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Weight Loss | 2015 |
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Republic of Korea; Stomach Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2015 |
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2015 |
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Dose-Response Relationship, Drug; Humans; Male; Maximum Tolerated Dose; Middle Aged; Safety; Stomach Neoplasms | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Stomach Neoplasms | 2015 |
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Stomach Neoplasms; Survival Rate | 2015 |
Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy.
Topics: Capecitabine; Chemotherapy, Adjuvant; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis | 2015 |
Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Stomach Neoplasms; Young Adult | 2015 |
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Receptor, ErbB-2; Stomach Neoplasms | 2015 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Kaplan-Meier Estimate; Male; Nausea; Pilot Projects; Prospective Studies; Stomach Neoplasms; Trastuzumab; Treatment Outcome; Vomiting | 2015 |
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Genetic Predisposition to Disease; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Disease-Free Survival; Docetaxel; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Taxoids; Trastuzumab | 2016 |
TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; Disease-Free Survival; Female; Genes, p53; Genotype; Humans; Male; Middle Aged; Paclitaxel; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms; Treatment Outcome | 2016 |
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoadjuvant Therapy; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Stomach Neoplasms | 2016 |
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Capsules; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase | 2016 |
A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Fluorouracil; Humans; Infections; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Panitumumab; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2016 |
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Taxoids | 2016 |
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease Progression; Female; Humans; Indazoles; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Sulfonamides; Young Adult | 2016 |
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Follow-Up Studies; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Pyrimidines; Stomach Neoplasms; Sulfonamides; Young Adult | 2016 |
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Topics: Acetylation; Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Disease-Free Survival; Fatigue; Female; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Protein Processing, Post-Translational; Stomach Neoplasms; Thromboembolism; Treatment Outcome; Vorinostat | 2016 |
Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Disease Progression; Female; Humans; Induction Chemotherapy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retreatment; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Disease Progression; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Neoplasm Staging; Polymorphism, Single Nucleotide; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Treatment Outcome | 2016 |
Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liposomes; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2016 |
A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids | 2016 |
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Interactions; Esophageal Neoplasms; Female; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proton Pump Inhibitors; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2017 |
Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplatin; Double-Blind Method; Drug Interactions; Epirubicin; Humans; Middle Aged; Models, Biological; Stomach Neoplasms; Young Adult | 2017 |
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Stomach Neoplasms | 2009 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2009 |
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Paraffin Embedding; Predictive Value of Tests; Stomach Neoplasms; Stromal Cells; Thymidine Phosphorylase | 2008 |
Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Deoxycytidine; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Failure; Treatment Outcome | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Remission Induction; Stomach Neoplasms; Survival Rate; Vomiting; Young Adult | 2008 |
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2008 |
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2008 |
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Palliative Care; Remission Induction; Salvage Therapy; Stomach Neoplasms | 2009 |
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Thromboembolism; United Kingdom; Warfarin | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 2009 |
Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2009 |
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms | 2010 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxaloacetates; Peripheral Nervous System Diseases; Remission Induction; Stomach Neoplasms; Survival Rate | 2009 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Adjuvant; Stomach Neoplasms | 2010 |
Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2010 |
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2010 |
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Prospective Studies; Recurrence; Stomach Neoplasms; Treatment Outcome | 2011 |
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids | 2010 |
[Preliminary study of XELOX regimen as the first-line chemotherapy in advanced or recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Stomach Neoplasms | 2010 |
[Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult | 2010 |
Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neutropenia; Oxaloacetates; Stomach Neoplasms; Survival; Treatment Outcome; Young Adult | 2010 |
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Outpatients; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2010 |
A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2010 |
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Stomach Neoplasms | 2010 |
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pravastatin; Stomach Neoplasms | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Treatment Outcome | 2010 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Young Adult | 2011 |
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Stomach Neoplasms; Time Factors; Treatment Outcome | 2012 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Vomiting | 2010 |
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Palliative Care; Stomach Neoplasms | 2012 |
Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2012 |
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Stomach Neoplasms; Treatment Outcome | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Research Design; Stomach Neoplasms | 2011 |
Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Placebos; Stomach Neoplasms; Survival Rate; Young Adult | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Hyponatremia; Japan; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Oxonic Acid; Quinazolines; Stomach Neoplasms; Tegafur; Treatment Outcome; Tumor Burden | 2012 |
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2011 |
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Japan; Male; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2012 |
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Young Adult | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate | 2012 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2012 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Stomach Neoplasms; Survival Rate; Thrombocytopenia; Vomiting | 2012 |
Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms | 2012 |
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2013 |
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2013 |
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2012 |
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2012 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Stomach Neoplasms; Stroke Volume; Thromboembolism; Treatment Outcome | 2013 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiovascular Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Recombinant Fusion Proteins; Stomach Neoplasms; Treatment Outcome; Young Adult | 2013 |
Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Treatment Outcome | 2012 |
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms | 2012 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Risk Assessment; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Stomach Neoplasms; Treatment Outcome | 2003 |
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Survival Analysis; Taxoids | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2004 |
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2005 |
Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids | 2005 |
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2005 |
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids | 2005 |
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2006 |
A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids | 2006 |
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2008 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Stomach Neoplasms; Survival Analysis | 2007 |
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2008 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids | 2007 |
A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy Dosage; Stomach Neoplasms | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Radiotherapy, Adjuvant; Stomach Neoplasms; Treatment Outcome | 2007 |
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids | 2007 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Quality of Life; Stomach Neoplasms; Survival Rate | 2008 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
271 other study(ies) available for capecitabine and Stomach Neoplasms
| Article | Year |
|---|---|
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population-Reply.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Oxaliplatin; Stomach Neoplasms | 2021 |
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Oxaliplatin; Stomach Neoplasms | 2021 |
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Oxaliplatin; Stomach Neoplasms | 2021 |
Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis.
Topics: Aerosols; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Cost-Benefit Analysis; Doxorubicin; Humans; Injections, Intraperitoneal; Laparoscopy; Oxaloacetates; Peritoneal Neoplasms; Quality-Adjusted Life Years; Stomach Neoplasms; United Kingdom | 2022 |
[A Long-Term Survival Case of Liver Metastasis from Remnant Gastric Cancer Treated by CapeOX, S-1, and Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxaliplatin; Positron Emission Tomography Computed Tomography; Stomach Neoplasms | 2021 |
A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Confidence Intervals; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Gene Frequency; Genes, p53; Genotype; Glutathione S-Transferase pi; Glycine Hydroxymethyltransferase; Humans; Leucovorin; Logistic Models; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Multienzyme Complexes; Nomograms; Odds Ratio; Organoplatinum Compounds; Orotate Phosphoribosyltransferase; Orotidine-5'-Phosphate Decarboxylase; Platinum Compounds; Polymorphism, Single Nucleotide; Pyrimidines; Quality of Life; Retrospective Studies; Stomach Neoplasms; Xeroderma Pigmentosum Group D Protein | 2021 |
Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Japan; Retrospective Studies; Stomach Neoplasms | 2022 |
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Docetaxel; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Perioperative Care; Propensity Score; Stomach Neoplasms; Treatment Outcome | 2022 |
Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Immunotherapy; Neoadjuvant Therapy; Nutrition Assessment; Oxaloacetates; Prognosis; Programmed Cell Death 1 Receptor; Prospective Studies; Retrospective Studies; Stomach Neoplasms | 2022 |
Kinesin family member 2A links with advanced tumor stage, reduced chemosensitivity and worse prognosis in gastric cancer.
Topics: Capecitabine; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kinesins; Oxaliplatin; Prognosis; RNA, Small Interfering; Stomach Neoplasms | 2022 |
Expression Profiles of Circulating MicroRNAs in XELOX-Chemotherapy-Induced Peripheral Neuropathy in Patients with Advanced Gastric Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Circulating MicroRNA; Gene Expression Profiling; Humans; MicroRNAs; Oxaloacetates; Peripheral Nervous System Diseases; Stomach Neoplasms | 2022 |
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Fluorouracil; Humans; Oxaliplatin; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2022 |
Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Fluorouracil; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2022 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
[Evaluation of the Usefulness of Pharmaceutical Outpatient Clinic for Gastric Cancer Patients Receiving Capecitabine plus Oxaliplatin as Postoperative Adjuvant Chemotherapy].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Fluorouracil; Humans; Oxaliplatin; Stomach Neoplasms | 2022 |
Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer.
Topics: Anemia; Capecitabine; Humans; Neoadjuvant Therapy; Radiotherapy, Image-Guided; Retrospective Studies; Stomach Neoplasms; Thrombocytopenia | 2022 |
Comprehensive information-based differential gene regulatory networks analysis (CIdrgn): Application to gastric cancer and chemotherapy-responsive gene network identification.
Topics: Cadherins; Capecitabine; Gene Regulatory Networks; Humans; Oxaliplatin; Stomach Neoplasms | 2023 |
Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 after gastrectomy: a population-based cohort study using a nationwide claims database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Stomach Neoplasms | 2023 |
Capecitabine-induced posterior reversible encephalopathy syndrome (PRES) in a patient with gastric adenocarcinoma.
Topics: Adenocarcinoma; Brain Diseases; Capecitabine; Female; Humans; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Seizures; Stomach Neoplasms | 2023 |
[Evaluation of the Leftover Capecitabine Tablets in Adjuvant CAPOX Chemotherapy for Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Fluorouracil; Humans; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Tablets | 2023 |
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Esophageal Neoplasms; Esophagogastric Junction; Exanthema; Fatigue; Female; Humans; Male; Margins of Excision; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Stomach Neoplasms; Vomiting | 2020 |
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prospective Studies; Stomach Neoplasms | 2020 |
Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2019 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Docetaxel; Emergency Service, Hospital; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; France; Germany; Guideline Adherence; Hospice Care; Hospitalization; Humans; Irinotecan; Male; Middle Aged; Nutritional Support; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptor, ErbB-2; Retrospective Studies; Spain; Stomach Neoplasms; Treatment Failure; United Kingdom | 2020 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2020 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2020 |
Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2020 |
The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Humans; Inflammation; Lymphocytes; Middle Aged; Monocytes; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaloacetates; Perioperative Period; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Young Adult | 2020 |
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Capecitabine; Case-Control Studies; China; Colorectal Neoplasms; Cyclooxygenase 2; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Polymorphism, Single Nucleotide; Prostaglandin-E Synthases; Receptors, Prostaglandin E; Risk Factors; Signal Transduction; Stomach Neoplasms; Young Adult | 2020 |
Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrectomy; Humans; Lymph Node Excision; Male; Microsatellite Instability; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Prospective Studies; Risk Assessment; Risk Factors; Stomach Neoplasms; Time Factors | 2021 |
Survival Advantages in Gastric Cancer Patients Receiving Preoperative SOX Regimen Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Humans; Oxaliplatin; Proportional Hazards Models; Stomach Neoplasms | 2023 |
Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Capecitabine; DNA Methylation; Docetaxel; Gene Expression Regulation; Humans; Oxaliplatin; Promoter Regions, Genetic; SOXF Transcription Factors; Stomach Neoplasms; Tumor Suppressor Proteins | 2020 |
Correlation between microRNA-766 expression in patients with advanced gastric cancer and the efficacy of platinum-containing chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome; Tumor Burden | 2020 |
Extending chemotherapy with capecitabine following CAPOX chemotherapy improves survival of Stage 3 gastric carcinoma after radical surgery: a 5-year analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Young Adult | 2020 |
Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Disease Management; Drug Combinations; Female; Hepatic Veno-Occlusive Disease; Humans; Incidence; Liver Function Tests; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Retrospective Studies; Spleen; Splenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2021 |
[Two Cases of Peritoneal Dissemination of Gastric Cancer Treated with CART Followed by Chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Female; Humans; Male; Middle Aged; Oxaliplatin; Peritoneal Neoplasms; Stomach Neoplasms | 2020 |
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2022 |
Effects of bevacizumab and capecitabine combined with intraperitoneal thermoperfusion chemotherapy on therapeutic effect, immunity and prognosis of gastric cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Humans; Prognosis; Stomach Neoplasms | 2022 |
Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Female; Genotype; Humans; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Stomach Neoplasms; Young Adult | 2021 |
Probiotic
Topics: Animals; Capecitabine; Humans; Lacticaseibacillus rhamnosus; Male; Mice; Mice, Inbred BALB C; Probiotics; Stomach Neoplasms | 2021 |
Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Biomarkers; Capecitabine; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Trastuzumab | 2022 |
Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Fluorouracil; Gastrectomy; Guideline Adherence; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Outcome and Process Assessment, Health Care; Oxaliplatin; Perioperative Care; Postoperative Complications; Practice Guidelines as Topic; Stomach Neoplasms; Survival Rate | 2022 |
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Perioperative Care; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2017 |
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer.
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Decision-Making; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nomograms; Organoplatinum Compounds; Oxaloacetates; Patient Selection; Postoperative Care; Pyrimidines; Stomach Neoplasms | 2017 |
Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Coronary Vasospasm; Drug Combinations; Drug Substitution; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Thalidomide; Treatment Outcome | 2018 |
[A Case of Long-Term Survival of a Patient with Gastric Cancer with Synchronous Liver Metastasis and Portal Vein Thrombus after Multidisciplinary Treatment].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur; Time Factors; Trastuzumab; Venous Thrombosis | 2017 |
Arterioportal shunt incidental to treatment with oxaliplatin that mimics recurrent gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arteriovenous Fistula; Biopsy; Capecitabine; Chemotherapy, Adjuvant; Diagnosis, Differential; Fluorouracil; Gastrectomy; Hepatic Artery; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Portal System; Positron Emission Tomography Computed Tomography; Splenectomy; Stomach Neoplasms; Ultrasonography; Withholding Treatment | 2017 |
Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer-Reply.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.
Topics: Capecitabine; Esophageal Neoplasms; Humans; Logic; Proton Pump Inhibitors; Stomach Neoplasms | 2018 |
Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2.
Topics: Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Drug Combinations; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Quality of Life; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome | 2018 |
Low reported taste function is associated with low preference for high protein products in advanced oesophagogastric cancer patients undergoing palliative chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Dietary Proteins; Esophageal Neoplasms; Female; Food Preferences; Humans; Male; Middle Aged; Oxaliplatin; Palliative Care; Stomach Neoplasms; Taste | 2019 |
[Long-Term Complete Response of Peritoneal Recurrence from Advanced Gastric Cancer Using CapeOx Therapy Following Radical Gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Gastrectomy; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome | 2017 |
[A Case of HER2-Positive Unresectable Gastric Cancer with Multiple Lymph Node and Liver Metastases Controlled Effectively by Combination Chemotherapy with Capecitabine, Oxaliplatin, and Trastuzumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Female; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2017 |
[The Case of HER2 Positive Advanced Gastric Cancer with Para-Aorta Lymph Node Recurrence Responding to Capecitabine plus CDDP plus Trastuzumab Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Capecitabine; Cisplatin; Humans; Lymphatic Metastasis; Male; Receptor, ErbB-2; Recurrence; Stomach Neoplasms; Trastuzumab | 2017 |
Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Capecitabine; Diagnostic Imaging; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Meningeal Carcinomatosis; Multimodal Imaging; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2018 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Nail Diseases; Nails; Neoplasm Recurrence, Local; Oxaloacetates; Stomach Neoplasms | 2018 |
[Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5].
Topics: Biomarkers, Tumor; Capecitabine; DNA Mismatch Repair; Humans; Microsatellite Instability; Neoplastic Syndromes, Hereditary; Stomach Neoplasms | 2018 |
Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.
Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophagectomy; Female; Gastrectomy; Humans; Induction Chemotherapy; Logistic Models; Lymph Node Excision; Male; Middle Aged; Mortality; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Splenectomy; Stomach Neoplasms | 2018 |
Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first-line chemotherapy with oxaliplatin and capecitabine: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy-Induced Febrile Neutropenia; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaliplatin; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Treatment Outcome | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pyridines; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2018 |
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Oxonic Acid; Propensity Score; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution | 2018 |
[Pulmonary Metastasis of Gastric Cancer as Carcinomatous Lymphangiosis at Five and Half Years after Surgery;Report of a Case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2018 |
When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Psoriasis; Skin; Stomach Neoplasms; Treatment Outcome | 2018 |
Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
Topics: Adult; Aged; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Stomach Neoplasms | 2018 |
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2019 |
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Postoperative Care; Prognosis; Stomach Neoplasms; Survival Rate | 2019 |
Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients.
Topics: Adult; Aged; Capecitabine; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Predictive Value of Tests; Retrospective Studies; Stomach Neoplasms; Tomography, X-Ray Computed | 2018 |
[CapeOX Therapy as a Salvage Treatment for Advanced Gastric Cancer Refractory to S-1, Cisplatin, Irinotecan, and Taxanes].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2018 |
Magic Mouthwash for Oral Mucositis: A Teachable Moment.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Humans; Male; Middle Aged; Mouthwashes; Sodium Bicarbonate; Sodium Chloride; Stomach Neoplasms; Stomatitis | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Obesity; Oxaliplatin; Palliative Care; Sarcopenia; Stomach Neoplasms | 2019 |
[A Case of an Elderly Patient with Unresectable HER2-Positive Gastric Cancer Successfully Treated by Chemotherapy Combined with Trastuzumab over a Long Period].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Humans; Male; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2018 |
[A Case of Advanced Gastric Cancer with Extensive Lymph Node Metastasis That Showed pCR to Preoperative Chemotherapy ContainingXP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Stomach Neoplasms | 2018 |
[A Case of Hepatic Resection after Neoadjuvant Chemotherapy for Single Liver Metastasis from Gastric Cancer with Positive Human Epidermal Growth Factor Receptor 2].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Gastrectomy; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2018 |
Teaching NeuroImages: Transient mutism associated with splenium lesion in capecitabine-induced leukoencephalopathy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Corpus Callosum; Diffusion Magnetic Resonance Imaging; Female; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Middle Aged; Mutism; Pyramidal Tracts; Stomach Neoplasms; Tomography, X-Ray Computed | 2019 |
Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Oxaliplatin; Perioperative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2019 |
Tumor Size Improves the Accuracy of the Prognostic Prediction of Lymph Node-Negative Gastric Cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Prognosis; Retrospective Studies; Stomach; Stomach Neoplasms; Treatment Outcome; Tumor Burden | 2019 |
Hyperammonemia after capecitabine associated with occult impairment of the urea cycle.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Female; Humans; Hyperammonemia; Stomach Neoplasms; Urea | 2019 |
Perioperative FLOT: new standard for gastric cancer?
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2019 |
Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Oxaliplatin; Perioperative Care; Propensity Score; Stomach Neoplasms | 2019 |
Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy.
Topics: Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Endoscopy, Digestive System; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; Neoplasm Recurrence, Local; Oxaliplatin; Polymorphism, Single Nucleotide; Stomach Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Mixed Tumor, Malignant; Oxaloacetates; Stomach Neoplasms; Treatment Outcome | 2019 |
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Prognosis; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate | 2019 |
Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2019 |
Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Choice Behavior; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Predictive Value of Tests; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Uracil | 2019 |
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Cohort Studies; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Outcome and Process Assessment, Health Care; Oxaloacetates; Oxonic Acid; Paraneoplastic Polyneuropathy; Stomach Neoplasms; Tegafur | 2019 |
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Stomach Neoplasms | 2013 |
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Sepsis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
New advances in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Etoposide; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Methotrexate; Organoplatinum Compounds; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Radiotherapy, Conformal; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2015 |
Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer.
Topics: Acenaphthenes; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Pyrroles; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; Young Adult | 2013 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Catheterization, Peripheral; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Perioperative Period; Pulmonary Embolism; Retrospective Studies; Stomach Neoplasms; Survival Rate; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2014 |
Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Markov Chains; Models, Molecular; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2014 |
Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaloacetates; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2013 |
[Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Oxaloacetates; Postoperative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2013 |
Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2013 |
[A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Receptor, ErbB-2; Salvage Therapy; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab | 2013 |
Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
Topics: Apoptosis; Capecitabine; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; MAP Kinase Signaling System; Orotic Acid; RNA, Small Interfering; Stomach Neoplasms; Thymidine Phosphorylase; Up-Regulation | 2013 |
Capecitabine-induced subacute cutaneous lupus erythematosus: report of a case with positive rechallenge test.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Stomach Neoplasms | 2013 |
High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Topics: Adult; Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2013 |
Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma?
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2013 |
Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; DNA; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Protein Binding; Simvastatin; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom | 2014 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2014 |
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Middle Aged; Models, Statistical; Oxaloacetates; Oxonic Acid; Probability; Quality-Adjusted Life Years; Stomach Neoplasms; Tegafur | 2013 |
[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2013 |
[Recurrent gastric cancer treated with fourth-line chemotherapy consisting of capecitabine and cisplatin leading to partial response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Staging; Recurrence; Salvage Therapy; Stomach Neoplasms | 2013 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Middle Aged; Muscle, Skeletal; Stomach Neoplasms | 2013 |
Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Dermatomyositis associated with capecitabine in the setting of malignancy.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy, Needle; Capecitabine; Deoxycytidine; Dermatomyositis; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Male; Risk Assessment; Stomach Neoplasms | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies; Stomach Neoplasms | 2014 |
[Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate | 2014 |
Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer.
Topics: Antineoplastic Agents; Biopsy; Capecitabine; Cell Cycle Proteins; China; Cisplatin; Deoxycytidine; DNA Methylation; Fluorouracil; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Retrospective Studies; Stomach Neoplasms; Ubiquitin-Protein Ligases | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Stomach Neoplasms | 2013 |
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2015 |
[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
Capecitabine induced colitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms | 2014 |
Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Cell Survival; Cisplatin; Clinical Trials, Phase II as Topic; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Middle Aged; Paclitaxel; Stomach Neoplasms; tau Proteins; Transfection; Treatment Outcome; Tubulin; Xenograft Model Antitumor Assays; Young Adult | 2014 |
[Clinical study of autologous cytokine-induced killer cells combined with XELOX regimen in the treatment of senile advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytokine-Induced Killer Cells; Deoxycytidine; Fluorouracil; Humans; Immunotherapy, Adoptive; Oxaloacetates; Prospective Studies; Stomach Neoplasms | 2014 |
Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxonic Acid; Palliative Care; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression; Humans; Immunohistochemistry; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Stomach Neoplasms; Thymidylate Synthase; Treatment Outcome | 2014 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Haptoglobins; Hematologic Diseases; Hemolytic-Uremic Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2014 |
Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gastrectomy; Humans; In Situ Hybridization, Fluorescence; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2014 |
IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Kidney; Kidney Diseases; Leucovorin; Male; Middle Aged; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Stomach Neoplasms | 2014 |
[Survey of the current status of capecitabine-induced hypertriglyceridemia].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms | 2014 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fatal Outcome; Fluorouracil; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Turkey; Young Adult | 2014 |
[Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Peritoneal Neoplasms; Stomach Neoplasms; Trastuzumab | 2014 |
Improving prognosis after surgery for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Sarcopenia; Stomach Neoplasms; Tomography, X-Ray Computed | 2015 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Models, Economic; Oxaloacetates; Oxonic Acid; Quality-Adjusted Life Years; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Female; Gastrectomy; Humans; Male; Stomach Neoplasms | 2015 |
Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Retrospective Studies; Safety; Stomach Neoplasms; Survival Rate; Time Factors | 2015 |
Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Topics: Adenocarcinoma; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Cell Count; Capecitabine; Cell Line, Tumor; Culture Media; Drug Screening Assays, Antitumor; Endothelial Progenitor Cells; Fluorouracil; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Morphogenesis; Platelet-Derived Growth Factor; Sincalide; Stomach Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
[Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Genotype; Humans; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2015 |
Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Retrospective Studies; Stomach Neoplasms; Young Adult | 2014 |
Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Oxaloacetates; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms | 2014 |
[A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Stomach Neoplasms; Trastuzumab | 2014 |
[A case of advanced gastric cancer with liver metastasis involving curative surgery after neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms; Trastuzumab | 2014 |
[A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms; Trastuzumab | 2014 |
[A case of advanced gastric cancer successfully treated with trastuzumab, capecitabine, and Cisplatin therapy followed by curative resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Stomach Neoplasms; Trastuzumab; Young Adult | 2014 |
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Lymphatic Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2014 |
[A case of early gastric cancer completely responding to adjuvant chemotherapy for advanced colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colon, Ascending; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
[A case of stage IV gastric cancer resected after chemotherapy with capecitabine plus cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Middle Aged; Neoplasm Staging; Stomach Neoplasms | 2015 |
Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer--a clinical prospective study of outcome and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Female; Humans; Incidence; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Prospective Studies; Pulmonary Embolism; Recurrence; Risk Factors; Stomach Neoplasms; Treatment Outcome; Venous Thrombosis | 2015 |
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2015 |
[A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2015 |
High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Perioperative Period; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer.
Topics: Angiogenic Proteins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA; Dose-Response Relationship, Drug; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; NF-kappa B; Quercetin; Signal Transduction; Stomach Neoplasms; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Analysis | 2015 |
Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Remission Induction; Risk Factors; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Low percentage of CD24hiCD27⁺CD19⁺ B cells decelerates gastric cancer progression in XELOX-treated patients.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte Subsets; B-Lymphocytes; Biomarkers, Pharmacological; Capecitabine; Carcinoma; CD24 Antigen; China; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Prognosis; Stomach Neoplasms; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2015 |
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capecitabine; Cell Nucleus; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphoproteins; Reference Values; Retrospective Studies; Sodium-Hydrogen Exchangers; Stomach Neoplasms; Treatment Outcome | 2015 |
Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Carcinoma, Small Cell; Case-Control Studies; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Multiple Primary; Paclitaxel; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate | 2015 |
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxaloacetates; Stomach Neoplasms | 2015 |
A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2015 |
[Stage IV Gastric Cancer Made Resectable Following a Chemotherapy Regimen That Included Trastuzumab-A Case Report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms; Trastuzumab | 2015 |
Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced Peripheral Neuropathy.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cold Temperature; Cornea; Epirubicin; Erythromelalgia; Esophageal Neoplasms; Female; Hot Temperature; Humans; Hyperalgesia; Liver Neoplasms; Male; Microscopy, Confocal; Middle Aged; Nerve Fibers; Nerve Regeneration; Neural Conduction; Organoplatinum Compounds; Oxaliplatin; Pain Threshold; Stomach Neoplasms; Trastuzumab; Vibration | 2015 |
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Upper Gastrointestinal Tract | 2016 |
[A Case of HER-2 Positive Advanced Gastric Cancer Responding to Capecitabine＋Cisplatin＋Trastuzumab Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Capecitabine; Cisplatin; Female; Gastrectomy; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2015 |
Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Case-Control Studies; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Monitoring; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Gastrectomy; Humans; In Situ Hybridization; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Oxaloacetates; Phenotype; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pilot Projects; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Rate | 2016 |
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Esophagogastric Junction; Female; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2016 |
[A Case of Gastric Cancer with Multiple Liver Metastases Treated with XP Chemotherapy and RFA Resulting in a Complete Response for a Long Time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheter Ablation; Cisplatin; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Time Factors | 2015 |
[A Case of Gastric Cancer with Adrenal Metastasis That Responded to Chemotherapy].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Fatal Outcome; Humans; Male; Recurrence; Stomach Neoplasms | 2015 |
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Stomach Neoplasms; Survival Rate; Transcriptome | 2016 |
The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study.
Topics: Aged; Antineoplastic Agents; Capecitabine; Cross-Sectional Studies; Esophageal Neoplasms; Female; Food Preferences; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Qualitative Research; Stomach Neoplasms | 2016 |
The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Floxuridine; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Uracil | 2016 |
Full robot-assisted gastrectomy: surgical technique and preliminary experience from a single center.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Blood Transfusion; Capecitabine; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Female; Gastrectomy; Humans; Infusions, Intravenous; Learning Curve; Male; Middle Aged; Operative Time; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Prospective Studies; Robotic Surgical Procedures; Stomach Neoplasms; Young Adult | 2016 |
Antibody Improves Survival in Gastric Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Disease-Free Survival; Epirubicin; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
Plasma and erythrocyte uptake of omega-3 fatty acids from an intravenous fish oil based lipid emulsion in patients with advanced oesophagogastric cancer.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Epirubicin; Erythrocyte Membrane; Erythrocytes; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Feasibility Studies; Female; Fish Oils; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphatidylcholines; Pilot Projects; Prospective Studies; Reproducibility of Results; Sample Size; Stomach Neoplasms; Treatment Outcome; United Kingdom | 2017 |
Germ Cell Tumor Targeting Chemotherapy in Gastric Adenocarcinoma with an Endodermal Sinus Tumor Component: A Case Report.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Capecitabine; Cisplatin; Endodermal Sinus Tumor; Etoposide; Humans; Male; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Tomography, X-Ray Computed | 2017 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2016 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Preoperative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
[A Case of HER2-Positive Stage IV Advanced Gastric Cancer Treated with Chemotherapy Combined with Trastuzumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2016 |
[A Case of Advanced Gastric Cancer with Severe Jaundice from Multiple Liver Metastases That Was Significantly Improved after Capecitabine plus Oxaliplatin Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Jaundice; Liver Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2016 |
[A Case of HER2-Positive Advanced Gastric Cancer with Multiple Liver Metastases Effectively Treated with Trastuzumab, Capecitabine, and Cisplatin Combination Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Gastrectomy; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2016 |
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Capecitabine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Platinum Compounds; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2017 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Parenteral; Male; Middle Aged; Oxaloacetates; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Stomach Neoplasms; Survival Rate | 2017 |
Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pharmacogenomic Testing; Pharmacogenomic Variants; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult | 2017 |
Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
Topics: Capecitabine; Drug Combinations; Fluorouracil; Humans; Network Meta-Analysis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
[Gastric Cancer Diagnosed with Metastasis of the Navel(Sister Mary Joseph's Nodule) - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Female; Gastrectomy; Humans; Sister Mary Joseph's Nodule; Skin Neoplasms; Stomach Neoplasms; Trastuzumab | 2016 |
[A Patient with HER2-Positive Stage IV Advanced Gastric Cancer Who Received Chemotherapy with Trastuzumab plus XP Followed by Conversion Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Humans; Male; Neoplasm Staging; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2016 |
[A Case of Advanced Gastric Cancer with Multiple Liver Metastases Successfully Treated with Capecitabine, Cisplatin, and Trastuzumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Humans; Liver Neoplasms; Male; Stomach Neoplasms; Trastuzumab | 2016 |
Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
Topics: Abdominal Abscess; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Laparoscopy; Laparotomy; Lymph Node Excision; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pancreatic Fistula; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Time-to-Treatment | 2017 |
The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Stomach Neoplasms; United Kingdom | 2017 |
Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost of Illness; Cost-Benefit Analysis; Female; Fluorouracil; Health Expenditures; Health Services; Hong Kong; Humans; Male; Middle Aged; Models, Econometric; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms | 2017 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Topics: Acute Disease; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Severity of Illness Index; Steroids; Stomach Neoplasms | 2008 |
Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2008 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Black or African American; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Stomach Neoplasms | 2008 |
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Rectal Neoplasms; Stomach Neoplasms; Treatment Outcome | 2009 |
Blepharoptosis following oxaliplatin administration.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Vision Disorders | 2009 |
Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Creatinine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kidney; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Stomach Neoplasms | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2009 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Frequency; Genetic Variation; Haplotypes; Humans; Introns; Male; Middle Aged; Mutation; Neoplasms; Polymorphism, Genetic; Sequence Analysis, DNA; Severity of Illness Index; Stomach Neoplasms; White People | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Vomiting; Young Adult | 2009 |
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Insurance, Health, Reimbursement; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; United States | 2009 |
Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Stomach Neoplasms | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Stomach Neoplasms | 2010 |
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2009 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2010 |
Cutaneous metastasis as first clinical manifestation of signet ring cell gastric carcinoma.
Topics: Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Signet Ring Cell; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Skin Neoplasms; Stomach Neoplasms; Taxoids | 2010 |
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Atrophy; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Erythema; Fluorouracil; Foot; Functional Laterality; Hand; Humans; Male; Stomach Neoplasms | 2010 |
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Netherlands; Proportional Hazards Models; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Stomach Neoplasms; Time Factors; Treatment Outcome | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Neoplasms; Risk Factors; Stomach Neoplasms | 2010 |
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids | 2010 |
Capecitabine with radiation is an effective adjuvant therapy in gastric cancers.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Denmark; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fever; Fluorouracil; Humans; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[Oxaliplatin plus capecitabine for advanced gastric cancer: report of 38 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2010 |
Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Colitis, Ischemic; Deoxycytidine; Endoscopy, Digestive System; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed | 2011 |
Trastuzumab for gastric cancer treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Humans; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2010 |
[A resected case of gastric regional lymph node metastasis from ascending colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colon, Ascending; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Staging; Remission Induction; Stomach Neoplasms | 2011 |
[Comparison of two types of digestive tract reconstruction after total gastrectomy in patients with gastric carcinoma].
Topics: Anastomosis, Roux-en-Y; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Jejunum; Nutritional Status; Oxaloacetates; Plastic Surgery Procedures; Postoperative Period; Quality of Life; Retrospective Studies; Stomach Neoplasms | 2011 |
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome; Tubulin | 2011 |
[Adjuvant chemotherapy for gastric cancer: more drugs do not mean better efficacy].
Topics: Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Postoperative Care; Prognosis; Retrospective Studies; Stomach Neoplasms | 2011 |
[Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Floxuridine; Fluorouracil; Humans; Plasmids; Recombinant Proteins; RNA, Messenger; Sensitivity and Specificity; Stomach Neoplasms; Thymidine Phosphorylase; Transfection | 2011 |
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Gastrectomy; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Risk Factors; Stomach Neoplasms; Venous Thromboembolism | 2011 |
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2011 |
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dehydration; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gastrectomy; Heart; Humans; Induction Chemotherapy; Kidney; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Comparing cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Urea Nitrogen; Capecitabine; Chemoradiotherapy; Creatinine; Cystatin C; Deoxycytidine; Female; Fluorouracil; Glomerular Filtration Rate; Humans; Iran; Kidney; Kidney Diseases; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Radiation Dosage; Radiation Injuries; Stomach Neoplasms; Time Factors; Treatment Outcome | 2012 |
[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Rate | 2011 |
First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chromans; Cyclin D1; Cyclooxygenase 2; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Intercellular Adhesion Molecule-1; Ki-67 Antigen; Matrix Metalloproteinase 9; Mice; Mice, Nude; Mitochondria; Neovascularization, Pathologic; NF-kappa B; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-bcl-2; Receptors, CXCR4; Repressor Proteins; Stomach Neoplasms; Survivin; Vascular Endothelial Growth Factor A; Vitamin E; Xenograft Model Antitumor Assays | 2012 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
Bilateral acute ptosis leading to the diagnosis of a presumed metastatic gastric adenocarcinoma.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capecitabine; Deoxycytidine; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Orbital Neoplasms; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Radiotherapy, Adjuvant; Stomach Neoplasms | 2012 |
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2013 |
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbachol; Chemotherapy, Adjuvant; Cholinergic Agonists; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Ganglia, Autonomic; Gastric Emptying; Gastric Mucosa; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Neoadjuvant Therapy; Stomach; Stomach Neoplasms | 2012 |
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prognosis; ROC Curve; Sensitivity and Specificity; Stomach Neoplasms; Tubulin; Young Adult | 2012 |
[A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Male; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2012 |
[A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
Topics: Adenocarcinoma, Scirrhous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fatal Outcome; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2012 |
Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Coix; Deoxycytidine; Docetaxel; Drugs, Chinese Herbal; Female; Fluorouracil; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phytotherapy; Prognosis; Quality of Life; Remission Induction; Seeds; Stomach Neoplasms; Taxoids; Young Adult | 2012 |
Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Paclitaxel; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Thymidylate Synthase | 2013 |
[Efficacy of capecitabine/cisplatin chemotherapy after failure of all conventional therapies in patients with advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms | 2013 |
[A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Combined Modality Therapy; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Oxaloacetates; Pilot Projects; Stomach Neoplasms; Treatment Outcome | 2013 |
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Incidence; Male; Severity of Illness Index; Stomach Neoplasms; Syndrome; Taxoids | 2003 |
Nail changes during docetaxel containing combination chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lymphatic Diseases; Middle Aged; Nail Diseases; Stomach Neoplasms; Taxoids | 2004 |
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms | 2004 |
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2005 |
Is adjuvant therapy with three-dimensional conformal irradiation combined with capecitabine (Xeloda) for gastric cancer effective?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Stomach Neoplasms | 2005 |
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pilot Projects; Stomach Neoplasms | 2006 |
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2006 |
Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Liver Failure; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Stomach Neoplasms | 2006 |
Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer.
Topics: Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Dermatitis; Diagnosis, Differential; Female; Fluorouracil; Humans; Middle Aged; Skin Neoplasms; Stomach Neoplasms; Treatment Outcome | 2007 |
Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Stomach Neoplasms; Survival Analysis | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Thymidine Phosphorylase | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD4-CD8 Ratio; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Endpoint Determination; Female; Fluorouracil; Humans; Immunotherapy; Killer Cells, Natural; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Analysis; Taxoids; Vascular Endothelial Growth Factor A | 2007 |
Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Patient Selection; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Capecitabine and irinotecan in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2007 |
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2007 |
Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Stomach Neoplasms | 2008 |
Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Hepatomegaly; Humans; Immunohistochemistry; Liver Neoplasms; Male; Risk Factors; Stomach Neoplasms; Tomography, X-Ray Computed; Tumor Lysis Syndrome | 2008 |
Oral treatment for gastric cancer: new choices, better choices?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Japan; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
Nail and periungual toxicity following capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Nail Diseases; Stomach Neoplasms; Treatment Outcome | 2008 |